<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        14-828-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VFEND 200MG POWDER FOR SOLU.FOR INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VORICONAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Parenteral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        327.80
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PHARMACIA UPJOHN" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PHARMACIA UPJOHN
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer Europe MA EEIG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J02AC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>VFEND contains the active substance voriconazole. VFEND is an antifungal medicine. It works by killing or stopping the growth of the fungi that cause infections.<br />&nbsp;</p><p>It is used for the treatment of patients (adults and children over the age of 2) with:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; invasive aspergillosis (a type of fungal infection due to <em>Aspergillus sp</em>),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; candidaemia (another type of fungal infection due to <em>Candida sp</em>) in non-neutropenic patients (patients without abnormally low white blood cells count),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious invasive <em>Candida sp.</em> infections when the fungus is resistant to fluconazole (another antifungal medicine),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious fungal infections caused by <em>Scedosporium sp.</em> or <em>Fusarium sp</em>. (two different species of fungi).</p><p>&nbsp;</p><p>VFEND is intended for patients with worsening, possibly life-threatening, fungal infections.</p><p>&nbsp;</p><p>Prevention of fungal infections in high risk bone marrow transplant recipients.</p><p>&nbsp;</p><p>This product should only be used under the supervision of a doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take VFEND</strong></p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to the active ingredient voriconazole, or to sulfobutylether beta cyclodextrin sodium (listed in section 6).</p><p>&nbsp;</p><p>It is very important that you inform your doctor or pharmacist if you are taking or have taken any other medicines, even those that are obtained without a prescription, or herbal medicines.</p><p>&nbsp;</p><p>The medicines in the following list must not be taken during your course of VFEND treatment:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Terfenadine (used for allergy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Astemizole (used for allergy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cisapride (used for stomach problems)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pimozide (used for treating mental illness)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Quinidine (used for irregular heart beat)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ivabradine (used for symptoms of chronic heart failure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rifampicin (used for treating tuberculosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efavirenz (used for treating HIV) in doses of 400 mg and above once daily</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carbamazepine (used to treat seizures)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phenobarbital (used for severe insomnia and seizures)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ergot alkaloids (e.g., ergotamine, dihydroergotamine; used for migraine)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sirolimus (used in transplant patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ritonavir (used for treating HIV) in doses of 400mg and more twice daily</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s Wort (herbal supplement)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Naloxegol (used to treat constipation specifically caused by pain medicines, called opioids, (e.g., morphine, oxycodone, fentanyl, tramadol, codeine))</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tolvaptan (u<strong>s</strong>ed to treat hyponatremia (low levels of sodium in your blood) or to slow kidney function decline in patients with polycystic kidney disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lurasidone (used to treat depression)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Venetoclax (used to treat patients with chronic lymphocytic leukaemia-CLL)</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before taking VFEND if:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had an allergic reaction to other azoles.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are suffering from, or have ever suffered from liver disease. If you have liver disease, your doctor may prescribe a lower dose of VFEND. Your doctor should also monitor your liver function while you are being treated with VFEND by doing blood tests.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are known to have cardiomyopathy, irregular heart beat, slow heart rate or an abnormality of electrocardiogram (ECG) called &lsquo;long QTc syndrome&rsquo;.</p><p><strong>&nbsp;</strong></p><p>You should avoid any sunlight and sun exposure while being treated. There is an increased chance of skin toxicity while taking VFEND. This can happen with or without taking other medicines like methotrexate. It is important to cover sun exposed areas of skin and use sunscreen with high sun protection factor (SPF), as an increased sensitivity of skin to the sun&rsquo;s UV rays can occur. This may be further increased by other medicines that sensitise the skin to sunlight, like methotrexate. These precautions are also applicable to children.</p><p><u>&nbsp;</u></p><p>While being treated with VFEND:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tell your doctor immediately if you develop</p><p>o&nbsp;&nbsp; sunburn</p><p>o&nbsp;&nbsp; severe skin rash or blisters&nbsp;</p><p>o&nbsp;&nbsp; bone pain</p><p>&nbsp;</p><p>If you develop skin disorders as described above, your doctor may refer you to a dermatologist, who after consultation may decide that it is important for you to be seen on a regular basis. There is a small chance that skin cancer could develop with long-term use of VFEND.</p><p>&nbsp;</p><p>If you develop signs of &lsquo;adrenal insufficiency&rsquo; where the adrenal glands do not produce adequate amounts of certain steroid hormones such as cortisol which may lead to symptoms such as: chronic, or long lasting fatigue, muscle weakness, loss of appetite, weight loss, abdominal pain, please tell your doctor.</p><p>&nbsp;</p><p>If you develop signs of &lsquo;Cushing&rsquo;s syndrome&rsquo; where the body produces too much of the hormone cortisol</p><p>which may lead to symptoms such as: weight gain, fatty hump between the shoulders, a rounded face, darkening of the skin on the stomach, thighs breasts, and arms, thinning skin, bruising easily, high blood sugar, excessive hair growth, excessive sweating, please tell your doctor.</p><p>&nbsp;</p><p>Your doctor should monitor the function of your liver and kidney by doing blood tests.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>VFEND should not be given to children younger than 2 years of age.</p><p>&nbsp;</p><p><strong>Other medicines and VFEND</strong></p><p>Please tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including those that are obtained without a prescription.</p><p>Some medicines, when taken at the same time as VFEND, may affect the way VFEND works or VFEND may affect the way they work.</p><p>&nbsp;</p><p>Tell your doctor if you are taking the following medicine, as treatment with VFEND at the same time should be avoided if possible:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ritonavir (used for treating HIV) in doses of 100 mg twice daily</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Glasdegib (used for treating cancer) &ndash; if you need to use both drugs your doctor will monitor your heart rhythm frequently</p><p>&nbsp;</p><p>Tell your doctor if you are taking either of the following medicines, as treatment with VFEND at the same time should be avoided if possible, and a dose adjustment of voriconazole may be required:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rifabutin (used for treating tuberculosis). If you are already being treated with rifabutin your blood counts and side effects to rifabutin will need to be monitored.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phenytoin (used to treat epilepsy). If you are already being treated with phenytoin your blood concentration of phenytoin will need to be monitored during your treatment with VFEND and your dose may be adjusted.<br />&nbsp;</p><p>Tell your doctor if you are taking any of the following medicines, as a dose adjustment or monitoring may be required to check that the medicines and/ or VFEND are still having the desired effect:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Warfarin and other anticoagulants (e.g., phenprocoumon, acenocoumarol; used to slow down clotting of the blood)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ciclosporin (used in transplant patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tacrolimus (used in transplant patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sulfonylureas (e.g., tolbutamide, glipizide, and glyburide) (used for diabetes)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Statins (e.g., atorvastatin, simvastatin) (used for lowering cholesterol)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Benzodiazepines (e.g., midazolam, triazolam) (used for severe insomnia and stress)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Omeprazole (used for treating ulcers)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oral contraceptives (if you take VFEND whilst using oral contraceptives, you may get side effects such as nausea and menstrual disorders)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vinca alkaloids (e.g., vincristine and vinblastine) (used in treating cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tyrosine kinase inhibitors (e.g., axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (used for treating cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tretinoin (used to treat leukaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Indinavir and other HIV protease inhibitors (used for treating HIV)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-nucleoside reverse transcriptase inhibitors (e.g., efavirenz, delavirdine, nevirapine) (used for treating HIV) (some doses of efavirenz can NOT be taken at the same time as VFEND)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Methadone (used to treat heroin addiction)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alfentanil and fentanyl and other short-acting opiates such as sufentanil (painkillers used for surgical procedures)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oxycodone and other long-acting opiates such as hydrocodone (used for moderate to severe pain)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-steroidal anti-inflammatory drugs (e.g., ibuprofen, diclofenac) (used for treating pain and inflammation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluconazole (used for fungal infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Everolimus (used for treating advanced kidney cancer and in transplant patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Letermovir (used for preventing cytomegalovirus (CMV) disease after bone marrow transplant)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ivacaftor: used to treat cystic fibrosis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flucloxacillin (antibiotic used against bacterial infections)</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>VFEND must not be used during pregnancy, unless indicated by your doctor. Effective contraception must be used in women of childbearing potential. Contact your doctor immediately if you become pregnant while being treated with VFEND.</p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>VFEND may cause blurring of vision or uncomfortable sensitivity to light. While affected, do not drive or operate any tools or machines. Tell your doctor if you experience this.</p><p>&nbsp;</p><p><strong>VFEND contains sodium</strong></p><p>This medicine contains sodium (main component of cooking/table salt).</p><p>&nbsp;</p><p><strong>VFEND contains cyclodextrins</strong></p><p>This medicine contains cyclodextrins in each vial. If you have a kidney disease, talk to your doctor before you receive this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p>&nbsp;</p><p>Your doctor will determine your dose depending on your weight and the type of infection you have.</p><p>&nbsp;</p><p>Your doctor may change your dose depending on your condition.</p><p>&nbsp;</p><p>The recommended dose for adults (including elderly patients) is as follows:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td><p><strong>Intravenous </strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Dose for the first 24 hours </strong></p></td><td style="vertical-align:bottom"><p>6 mg/kg every 12 hours for the</p></td></tr><tr><td style="vertical-align:top"><p>(Loading Dose)</p></td><td style="vertical-align:top"><p>first 24 hours</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Dose after the first 24 hours </strong></p></td><td style="vertical-align:bottom"><p>4 mg/kg twice a day</p></td></tr><tr><td style="vertical-align:top"><p>(Maintenance Dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Depending on your response to treatment, your doctor may decrease the dose to 3 mg/kg twice daily.</p><p>&nbsp;</p><p>The doctor may decide to decrease the dose if you have mild to moderate cirrhosis.</p><p>&nbsp;</p><p><strong>Use in children and adolescents</strong></p><p>The recommended dose for children and teenagers is as follows:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2"><p><strong>Intravenous </strong></p></td></tr><tr><td><p>Children aged 2 to less than 12&nbsp;years and teenagers aged 12 to 14 years weighing less than 50&nbsp;kg</p></td><td><p>Teenagers aged 12 to 14 years weighing 50 kg or more; and all teenagers older than 14</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dose for the first 24 hours </strong></p><p>(Loading Dose)</p></td><td><p>9&nbsp;mg/kg every 12 hours for the first 24 hours</p></td><td><p>6&nbsp;mg/kg every 12 hours for the first 24 hours</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Dose after the first 24 hours </strong></p></td><td style="vertical-align:bottom"><p>8&nbsp;mg/kg twice a day</p></td><td style="vertical-align:bottom"><p>4&nbsp;mg/kg twice a day</p></td></tr><tr><td style="vertical-align:top"><p>(Maintenance Dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Depending on your response to treatment, your doctor may increase or decrease the daily dose.</p><p><strong>&nbsp;</strong></p><p>VFEND powder for solution for infusion will be reconstituted and diluted to the correct concentration by your hospital pharmacist or nurse. (Please refer to the end of this leaflet for further information)&nbsp;&nbsp;</p><p>&nbsp;</p><p>This will be given to you by intravenous infusion (into a vein) at a maximum rate of 3&nbsp;mg/kg per hour over 1&nbsp;to 3&nbsp;hours.<br />&nbsp;</p><p>If you or your child are taking VFEND for prevention of fungal infections, your doctor may stop giving VFEND if you or your child develop treatment related side effects.</p><p>&nbsp;</p><p><strong>If a dose of VFEND has been forgotten</strong></p><p>As you will be given this medicine under close medical supervision, it is unlikely that a dose would be missed. However tell your doctor or pharmacist if you think that a dose has been forgotten.</p><p>&nbsp;</p><p><strong>If you stop taking VFEND </strong></p><p>VFEND treatment will continue for as long as your doctor advises, however duration of treatment with VFEND powder for solution for infusion should be no more than 6 months.</p><p>&nbsp;</p><p>Patients with a weakened immune system or those with difficult infections may require long-term treatment to prevent the infection from returning. You may be switched from the intravenous infusion to tablets once your condition improves.</p><p>&nbsp;</p><p>When VFEND treatment is stopped by your doctor you should not experience any effects.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>If any side effects occur, most are likely to be minor and temporary. However, some may be serious and need medical attention.</p><p>&nbsp;</p><p><strong>Serious side effects &ndash; Stop taking VFEND and see a doctor immediately</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jaundice; Changes in blood tests of liver function</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pancreatitis</p><p>&nbsp;</p><p><strong>Other side effects</strong></p><p>&nbsp;</p><p>Very common: may affect more than 1 in 10 people</p><p>&nbsp;</p><p><strong>-</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Visual impairment (change in vision including blurred vision, visual colour alterations, abnormal intolerance to visual perception of light, colour blindness, eye disorder, halo vision, night blindness, swinging vision, seeing sparks, visual aura, visual acuity reduced, visual brightness, loss of part of the usual field of vision, spots before the eyes)</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea, vomiting, diarrhoea</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the extremities</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach pains</p><p><strong>-</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breathing difficulties</p><p><strong>-</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elevated liver enzymes</p><p>&nbsp;</p><p>Common: may affect up to 1 in 10 people</p><p>&nbsp;</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the sinuses, inflammation of the gums, chills, weakness</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low numbers of some types, including severe, of red (sometimes immune-related) and/or white blood cells (sometimes with fever), low numbers of cells called platelets that help the blood to clot</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood sugar, low blood potassium, low sodium in the blood</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anxiety, depression, confusion, agitation, inability to sleep, hallucinations</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seizures, tremors or uncontrolled muscle movements, tingling or abnormal skin sensations, increase in muscle tone, sleepiness, dizziness</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding in the eye</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart rhythm problems including very fast heartbeat, very slow heartbeat, fainting</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure, inflammation of a vein (which may be associated with the formation of a blood clot)</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute breathing difficulty, chest pain, swelling of the face (mouth, lips and around eyes), fluid accumulation in the lungs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation, indigestion, inflammation of the lips</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jaundice, inflammation of the liver and liver injury</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rashes which may lead to severe blistering and peeling of the skin characterized by a flat, red area on the skin that is covered with small confluent bumps, redness of the skin</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itchiness</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Back pain</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney failure, blood in the urine, changes in kidney function tests</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sunburn or severe skin reaction following exposure to light or sun</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin cancer</p><p>&nbsp;</p><p>Uncommon: may affect up to 1 in 100 people</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flu-like symptoms, irritation and inflammation of the gastrointestinal tract, inflammation of the gastrointestinal tract causing antibiotic associated diarrhoea, inflammation of the lymphatic vessels</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the thin tissue that lines the inner wall of the abdomen and covers the abdominal organ</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Enlarged lymph glands (sometimes painful), failure of blood marrow, increased eosinophil</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depressed function of the adrenal gland, underactive thyroid gland</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal brain function, Parkinson-like symptoms, nerve injury resulting in numbness, pain, tingling or burning in the hands or feet</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems with balance or coordination</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the brain&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Double vision, serious conditions of the eye including: pain and inflammation of the eyes and eyelids, abnormal eye movement, damage to the optic nerve resulting in vision impairment, optic disc swelling</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased sensitivity to touch</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal sense of taste</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hearing difficulties, ringing in the ears, vertigo</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of certain internal organs- pancreas and duodenum, swelling and inflammation of the tongue</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Enlarged liver, liver failure, gallbladder disease, gallstones</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint inflammation, inflammation of the veins under the skin (which may be associated with the formation of a blood clot)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the kidney, proteins in the urine, damage to the kidney&nbsp;</p><p><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very fast heart rate or skipped heartbeats, sometimes with erratic electrical impulses</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal electrocardiogram (ECG)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood cholesterol increased, blood urea increased</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic skin reactions (sometimes severe), including life-threatening skin condition that causes painful blisters and sores of the skin and mucous membranes, especially in the mouth, inflammation of the skin, hives, skin redness and irritation, red or purple discoloration of the skin which may be caused by low platelet count, eczema</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infusion site reaction</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reaction or exaggerated immune response</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the tissue surrounding the bone&nbsp;</p><p>&nbsp;</p><p>Rare: may affect up to 1 in 1000 people</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Overactive thyroid gland</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deterioration of brain function that is a serious complication of liver disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of most fibers in the optic nerve, clouding of the cornea, involuntary movement of the eye</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bullous photosensitivity</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A disorder in which the body&rsquo;s immune system attacks part of the peripheral nervous system</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart rhythm or conduction problems (sometimes life threatening)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Life threatening allergic reaction</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disorder of blood clotting system</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic skin reactions (sometimes severe), including rapid swelling (oedema) of the dermis, subcutaneous tissue, mucosa and submucosal tissues, itchy or sore patches of thick, red skin with silvery scales of skin, irritation of the skin and mucous membranes, life-threatening skin condition that causes large portions of the epidermis, the skin&#39;s outermost layer, to detach from the layers of skin below</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Small dry scaly skin patches, sometimes thick with spikes or &lsquo;horns&rsquo;</p><p>&nbsp;</p><p>Side effects with frequency not known:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Freckles and pigmented spots</p><p>&nbsp;</p><p>Other significant side effects whose frequency is not known, but should be reported to your doctor immediately:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Red, scaly patches or ring-shaped skin lesions that may be a symptom of an autoimmune disease called cutaneous lupus erythematosus</p><p><s>&nbsp;</s></p><p>Reactions during the infusion have occurred uncommonly with VFEND (including flushing, fever, sweating, increased heart rate and shortness of breath). Your doctor may stop the infusion if this occurs.</p><p>&nbsp;</p><p>As VFEND has been known to affect the liver and the kidney, your doctor should monitor the function of your liver and kidney by doing blood tests. Please advise your doctor if you have any stomach pains or if your stools have a different consistency.</p><p>&nbsp;</p><p>There have been reports of skin cancer in patients treated with VFEND for long periods of time.</p><p>&nbsp;</p><p>Sunburn or severe skin reaction following exposure to light or sun was experienced more frequently in children. If you or your child develops skin disorders, your doctor may refer you to a dermatologist, who after consultation may decide that it is important for you or your child to be seen on a regular basis. Elevated liver enzymes were also observed more frequently in children.</p><p>&nbsp;</p><p>If any of these side effects persist or are troublesome, please tell your doctor.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>T</strong><strong>o report any side effect(s):</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Center (NPC):</p><ul><li>SFDA Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/</li></ul></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other </strong><strong>GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Shelf life: 36 months.<br />&nbsp;</p><p>Vial should be stored below 30&deg;C.</p><p>&nbsp;</p><p>Once reconstituted, VFEND should be used immediately, but if necessary may be stored for up to 24 hours at 2&deg;C - 8&deg;C (in a refrigerator). Reconstituted VFEND needs to be diluted with a compatible infusion solution first before it is infused. (Please refer to the end of this leaflet for further information).</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer required. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is voriconazole.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredient is sulfobutylether beta cyclodextrin sodium (see section 2, VFEND 200&nbsp;mg powder for solution for infusion contains cyclodextrin and sodium).</p><p>&nbsp;</p><p>Each vial contains 200 mg voriconazole, equivalent to a 10 mg/ml solution when reconstituted as directed by your hospital pharmacist or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                VFEND is presented in single use glass vials as a powder for solution for infusion. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>Pfizer Europe MA EEIG, Belgium.</p><p>&nbsp;</p><p><strong>Manufacturer </strong></p><p>Pharmacia &amp; Upjohn Company LLC, 7000 Portage Road Kalamazoo, MI 49001, United States</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي فيفند على المادة الفعالة فوريكونازول. فيفند هو دواء مضاد للفطريات. وهو يعمل عن طريق قتل الفطريات المسببة للعدوى أو إيقاف نموها.<br />&nbsp;</p><p dir="RTL">يستخدم فيفند لعلاج المرضى (البالغين والأطفال أكبر من عامين):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المصابين بداء الرشاشيات الغازي (أحد أنواع العدوى الفطرية التي يسببها نوع الرشاشيات (أسبرجيلوس))،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الذين يعانون من وجود المبيضات في الدم (نوع آخر من العدوى الفطرية التي يسببها نوع المبيضات (كانديدا))، وذلك في حالة المرضى غير المصابين بقلة العدلات (المرضى الذين لا يعانون من انخفاض غير طبيعي في تعداد خلايا الدم البيضاء)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المصابين بحالات خطيرة من عدوى نوع المبيضات (كانديدا) الغازية، عندما يكون الفطر مقاومًا للعلاج بفلوكونازول (دواء آخر مضاد للفطريات)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المصابين بحالات خطيرة من العدوى الفطرية التي يسببها نوع البوغانة (سيدوسبوريوم) أو نوع المغزلاوية (فيوزاريوم). (نوعان مختلفان من الفطريات).</p><p dir="RTL">&nbsp;</p><p dir="RTL">فيفند مخصص لعلاج المرضى المصابين بحالات العدوى الفطرية المتفاقمة التي يُحتمل أن تكون مهددة للحياة.</p><p dir="RTL">منع الإصابة بالعدوى الفطرية في المرضى الذين خضعوا لعملية زراعة نخاع العظم المعرضين لخطر مرتفع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي استخدام هذا المنتج فقط تحت إشراف طبيب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>موانع استعمال فيفند</strong></p><p dir="RTL"><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الحساسية تجاه المكون الفعال فوريكونازول، أو تجاه سلفوبوتيل إيثر بيتا سيكلودكسترين الصوديوم (المذكورين في القسم ٦).</p><p dir="RTL">من المهم للغاية أن تبلغ طبيبك أو الصيدلي إذا كنت تتناول أو تناولت في السابق أي أدوية أخرى، حتى تلك التي يتم الحصول عليها دون وصفة طبية، أو الأدوية العشبية.</p><p dir="RTL">يجب عدم تناول الأدوية المذكورة في القائمة التالية أثناء فترة علاجك بفيفند:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيرفينادين (يستخدم لعلاج الحساسية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أستيميزول (يستخدم لعلاج الحساسية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيسابريد (يستخدم لعلاج مشكلات المعدة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بيموزيد (يستخدم لعلاج الأمراض العقلية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كينيدين (يستخدم لعلاج عدم انتظام ضربات القلب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيفابرادين (يستخدم لعلاج أعراض فشل القلب المزمن)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين (يستخدم لعلاج السل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيفافيرينز (يستخدم لعلاج فيروس نقص المناعة البشرية (HIV)) بجرعات تبلغ ٤٠٠ ملجم فأكثر مرة واحدة يوميًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاربامازيبين (يستخدم لعلاج النوبات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينوباربيتال (يستخدم لعلاج الحالات الشديدة من الأرق والنوبات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلويدات الإرجوت (مثل إرجوتامين، ثنائي هيدروإرجوتامين؛ يستخدمان لعلاج الصداع النصفي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيروليموس (يستخدم مع المرضى الخاضعين لعمليات زراعة الأعضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريتونافير (يستخدم لعلاج فيروس نقص المناعة البشرية) بجرعات تبلغ ٤٠٠ ملجم فأكثر مرتين يوميًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جون (مكمل عشبي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نالوكسيجول: (يستخدم لعلاج الإمساك خاصة الناتج عن أدوية تخفيف الألم، التي تسمى الأفيونات، (مثل مورفين، أوكسيكودون، فينتانيل، ترامادول، كودين))</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تولفابتان (يستخدم لعلاج نقص صوديوم الدم (مستويات منخفضة من الصوديوم في دمك) أو لإبطاء تدهور وظائف الكلى في المرضى المصابين بمرض الكلى متعددة الكيسات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لوراسيدون (يستخدم لعلاج الاكتئاب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوسلاكس (يستخدم لعلاج المرضى المصابين بابيضاض الدم الليمفاوي المزمن (CLL))</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال فيفند</strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي أو الممرضة قبل تناول فيفند:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت من قبل بتفاعل حساسية تجاه مركبات آزولية أخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أو عانيت في السابق من مرض بالكبد. إذا كنت مصابًا بمرض بالكبد، فقد يصف طبيبك جرعة أقل من فيفند. ينبغي أن يقوم طبيبك أيضًا بمراقبة وظائف كبدك أثناء خضوعك للعلاج بفيفند عن طريق إجراء فحوصات للدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان معروفًا أنك مصاب باعتلال عضلة القلب، أو تعاني من عدم انتظام ضربات القلب، أو بطء معدل نبضات القلب، أو اضطراب في رسم القلب (ECG) يُسمى &quot;متلازمة فترة QT المصححة الطويلة&quot;.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">ينبغي أن تتجنب أي تعرض للشمس أو ضوء الشمس أثناء خضوعك للعلاج. تتزايد فرصة الإصابة بسمية الجلد أثناء تناول فيفند. وقد يحدث هذا مع تناول أدوية أخرى مثل ميثوتريكسات أو من دونه. ومن المهم تغطية مناطق الجلد المُعرَّضة للشمس واستخدام واقٍ من الشمس يحتوي على نسبة عالية من عامل الحماية من الشمس (SPF)؛ إذ يمكن أن تحدث زيادة في حساسية الجلد لأشعة الشمس فوق البنفسجية (UV). يمكن أن تزداد فرصة حدوث هذا أيضًا بسبب أدوية أخرى تزيد من حساسية الجلد لأشعة الشمس مثل ميثوتريكسات. تنطبق هذه الاحتياطات أيضًا على الأطفال.</p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL">أثناء خضوعك للعلاج بفيفند:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك فورًا إذا أصبت</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بحروق شمس</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطفح جلدي شديد أو بثور&nbsp;</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بألم في العظم</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبت بأي اضطرابات في الجلد كما هو موضح أعلاه، فقد يحيلك طبيبك إلى طبيب أمراض جلدية، الذي قد يقرر بعد الاستشارة أنه من المهم فحصك بشكل منتظم. يوجد احتمال ضئيل للإصابة بسرطان الجلد مع الاستخدام طويل الأمد لفيفند<strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبت بعلامات &quot;قصور الغدة الكظرية&quot; حيث لا تنتج الغدد الكظرية كميات كافية من بعض الهرمونات الستيرويدية مثل الكورتيزول مما قد يؤدي إلى الإصابة بأعراض مثل: الإرهاق المزمن أو طويل الأمد، ضعف العضلات، فقدان الشهية، خسارة الوزن، ألم البطن، يرجى إخبار طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا ظهرت عليك علامات &quot;متلازمة كوشينج&quot; التي ينتج فيها الجسم كمية أكبر من اللازم من هرمون الكورتيزول الذي قد يؤدي إلى أعراض مثل: زيادة الوزن، وظهور نتوء من الدهون بين الكتفين، واستدارة الوجه، واسمرار الجلد على البطن، والفخذين، والثديين، والذراعين، وترقق الجلد، وسهولة التكدم، وارتفاع نسبة السكر في الدم، وزيادة نمو الشعر، والتعرق المفرط، يُرجى إخبار طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي أن يقوم طبيبك بمراقبة وظائف كبدك وكليتيك عن طريق إجراء فحوصات للدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">ينبغي عدم إعطاء فيفند للأطفال الذين تقل أعمارهم عن عامين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى، بما في ذلك تلك التي يتم الحصول عليها دون وصفة طبية.</p><p dir="RTL">فقد تؤثر بعض الأدوية، عند تناولها بالتزامن مع فيفند، على آلية عمل فيفند أو قد يؤثر فيفند على آلية عملها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول الدواء التالي، حيث ينبغي تجنب العلاج بفيفند بالتزامن معه إن أمكن:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريتونافير (يستخدم لعلاج فيروس نقص المناعة البشرية) بجرعات قدرها ١٠٠ ملجم مرتين يوميًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلاسديجيب (يستخدم لعلاج السرطان) &ndash; إذا احتجت إلى استخدام كلا العقارين، فسيراقب طبيبك نظم قلبك بصفة متكررة</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أيًا من الدواءين التاليين، حيث ينبغي تجنب العلاج بفيفند بالتزامن معهما إن أمكن، وقد يلزم تعديل جرعة فوريكونازول:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفابوتين (يستخدم لعلاج السل). إذا كنت تخضع بالفعل للعلاج بريفابوتين، فسيلزم مراقبة تعدادات دمك وآثار ريفابوتين الجانبية التي تظهر لديك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوين (يستخدم لعلاج الصرع). إذا كنت تخضع بالفعل للعلاج بفينيتوين، فسيلزم مراقبة تركيز فينيتوين في دمك أثناء علاجك بفيفند وقد يتم تعديل جرعتك.<br />&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أيًا من الأدوية التالية؛ إذ قد يلزم تعديل الجرعة أو الخضوع للمراقبة للتحقق من أن التأثير المرغوب لتلك الأدوية و/أو فيفند لا يزال كما هو:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وارفارين ومضادات التجلط الأخرى (مثل فينبروكومون، أسينوكومارول؛ يستخدمان لإبطاء عملية تخثر الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين (يستخدم مع المرضى الخاضعين لعمليات زراعة الأعضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تاكروليموس (يستخدم مع المرضى الخاضعين لعمليات زراعة الأعضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركبات السلفونيل يوريا (مثل تولبوتاميد، وجليبيزيد، وجليبوريد) (تستخدم لعلاج داء السكري)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الستاتينات (مثل أتورفاستاتين، سيمفاستاتين) (تستخدم لخفض الكولستيرول)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البنزوديازيبينات (مثل ميدازولام، تريازولام) (تستخدم لعلاج الحالات الشديدة من الأرق والتوتر)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوميبرازول (يستخدم لعلاج القرح)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موانع الحمل التي تؤخذ عن طريق الفم (إذا تناولتِ فيفند أثناء استخدام موانع الحمل التي تؤخذ عن طريق الفم، فقد تصابين بآثار جانبية مثل الغثيان واضطرابات الحيض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلويدات الونكا (مثل فينكريستين وفينبلاستين) (تستخدم في علاج السرطان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات كيناز التيروزين (مثل أكسيتينيب، بوسوتينيب، كابوزانتينيب، سيريتينيب، كوبيميتينيب، دابرافينيب، داساتينيب، نيلوتينيب، سونيتينيب، إيبروتينيب، ريبوسيكليب) (تستخدم لعلاج السرطان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تريتينوين (يستخدم لعلاج ابيضاض الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إندينافير والمثبطات الأخرى لإنزيم بروتياز فيروس نقص المناعة البشرية (تستخدم لعلاج فيروس نقص المناعة البشرية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المثبطات غير النيوكليوزيدية لإنزيم المنتسخة العكسية (مثل إيفافيرينز، ديلافيردين، نيفيرابين) (تستخدم لعلاج فيروس نقص المناعة البشرية) (بعض جرعات إيفافيرينز لا يمكن تناولها في نفس الوقت مع فيفند)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثادون (يستخدم لعلاج إدمان الهيروين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألفينتانيل وفينتانيل والمواد الأفيونية الأخرى قصيرة المفعول مثل سوفينتانيل (مسكنات ألم تستخدم في الإجراءات الجراحية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوكسيكودون والمواد الأفيونية الأخرى طويلة المفعول مثل هيدروكودون (تستخدم لتسكين الآلام المتوسطة إلى الشديدة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الالتهاب غير الستيرويدية (مثل إيبوبروفين، ديكلوفيناك) (تستخدم لعلاج الألم والالتهاب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فلوكونازول (يستخدم لعلاج حالات العدوى الفطرية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيفيروليموس (يستخدم لعلاج سرطان الكلى المتقدم ومع المرضى الخاضعين لعمليات زراعة الأعضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ليتيرموفير (يستخدم لمنع الإصابة بمرض الفيروس المضخم للخلايا (CMV) بعد إجراء زراعة نخاع العظم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيفاكافتور: يستخدم لعلاج التليف الكيسي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فلوكلوكساسلين (مضاد حيوي يستخدم لعلاج حالات العدوى البكتيرية)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">يجب عدم استخدام فيفند أثناء الحمل، إلا إذا أشار طبيبكِ بذلك. يجب على النساء القادرات على الإنجاب استخدام وسيلة فعالة لمنع الحمل. اتصلي بطبيبكِ فورًا إذا أصبحتِ حاملًا أثناء خضوعكِ للعلاج بفيفند.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ ربما تكونين حاملًا، أو تخططين للإنجاب، فاستشيري طبيبكِ أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير فيفند على القيادة واستخدام الآلات</strong></p><p dir="RTL">يمكن أن يسبب فيفند تغيمًا في الرؤية أو حساسية مزعجة تجاه الضوء. لا تقم بالقيادة أو تشغيل أي أدوات أو آلات عندما تكون تحت تأثير الدواء. أخبر طبيبك إذا أصبت بهذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات فيفند</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي فيفند على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على الصوديوم (المكون الرئيسي للطهي/ملح الطعام).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>فيفند يحتوي على ديكسترينات حلقية</strong></p><p dir="RTL">يحتوي هذا الدواء على ديكسترينات حلقية . إذا كنت مصابًا بمرض كلوي، فتحدث إلى طبيبك قبل تلقي هذا الدواء.</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك. استشر طبيبك إذا لم تكن متأكدًا مما يجب عليك فعله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيحدد طبيبك جرعتك بناءً على وزنك ونوع العدوى التي تعاني منها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وقد يغير طبيبك الجرعة التي تتلقاها بناءً على حالتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها للبالغين (بما في ذلك المرضى المسنين) هي كالتالي:</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td><p dir="RTL"><strong>عبر الوريد </strong></p></td></tr><tr><td style="vertical-align:bottom"><p dir="RTL"><strong>الجرعة لأول ٢٤ ساعة </strong></p></td><td style="vertical-align:bottom"><p dir="RTL">٦ ملجم/كلجم كل ١٢ ساعة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">(جرعة التحميل)</p></td><td style="vertical-align:top"><p dir="RTL">لأول ٢٤ ساعة</p></td></tr><tr><td style="vertical-align:bottom"><p dir="RTL"><strong>الجرعة بعد أول ٢٤ ساعة </strong></p></td><td style="vertical-align:bottom"><p dir="RTL">٤ ملجم/كلجم مرتين في اليوم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">(جرعة المداومة)</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">بناءً على استجابتك للعلاج، قد يخفض طبيبك الجرعة إلى ٣ ملجم/كلجم مرتين يوميًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وقد يقرر الطبيب خفض الجرعة إذا كنت مصابًا بتليف كبدي خفيف إلى متوسط.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام مع الأطفال والمراهقين</strong></p><p dir="RTL">الجرعة الموصى بها للأطفال والمراهقين هي كالتالي:</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td colspan="2"><p dir="RTL"><strong>عبر الوريد </strong></p></td></tr><tr><td><p dir="RTL">الأطفال من سن عامين إلى أقل من ١٢ عامًا والمراهقون من سن ١٢ إلى ١٤ عامًا ممن يبلغ وزنهم أقل من ٥٠ كلجم</p></td><td><p dir="RTL">المراهقون من سن ١٢ إلى ١٤ عامًا ممن يبلغ وزنهم ٥٠ كلجم أو أكثر؛ وجميع المراهقين الأكبر من ١٤ عامًا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الجرعة لأول ٢٤ ساعة </strong></p><p dir="RTL">(جرعة التحميل)</p></td><td><p dir="RTL">٩ ملجم/كلجم كل ١٢ ساعة لأول ٢٤ ساعة</p></td><td><p dir="RTL">٦ ملجم/كلجم كل ١٢ ساعة لأول ٢٤ ساعة</p></td></tr><tr><td style="vertical-align:bottom"><p dir="RTL"><strong>الجرعة بعد أول ٢٤ ساعة </strong></p></td><td style="vertical-align:bottom"><p dir="RTL">٨ ملجم/كلجم مرتين في اليوم</p></td><td style="vertical-align:bottom"><p dir="RTL">٤ ملجم/كلجم مرتين في اليوم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">(جرعة المداومة)</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">بناءً على استجابتك للعلاج، قد يزيد طبيبك الجرعة اليومية أو يخفضها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقوم صيدلي أو ممرضة المستشفى الخاصة بك بتحضير مسحوق فيفند المخصص لإعداد محلول للتسريب وتخفيفه إلى التركيز الصحيح. (يُرجى الرجوع إلى نهاية هذه النشرة للاطلاع على المزيد من المعلومات)&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيتم إعطاؤك هذا الدواء من خلال التسريب عبر الوريد (في أحد الأوردة) بمعدل يبلغ ٣ ملجم/كلجم في الساعة كحد أقصى على مدار فترة تتراوح بين ساعة و٣ ساعات.<br />&nbsp;</p><p dir="RTL">إذا كنت أنت أو طفلك تتناولان فيفند لمنع حالات العدوى الفطرية، فقد يتوقف طبيبك عن إعطاء فيفند إذا أصبت أنت أو طفلك بآثار جانبية ذات صلة بالعلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة فيفند</strong></p><p dir="RTL">نظرًا لأن هذا الدواء سوف يُعطى لك تحت إشراف طبي دقيق، فمن غير المرجح أن يتم تفويت إحدى الجرعات. وبالرغم من ذلك، فأخبر طبيبك أو الصيدلي إذا اعتقدت أنه قد تم نسيان إحدى الجرعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول فيفند </strong></p><p dir="RTL">سيستمر العلاج بفيفند طوال المدة التي ينصح بها طبيبك، ولكن مدة العلاج بمسحوق فيفند المخصص لإعداد محلول للتسريب ينبغي ألا تتجاوز ٦ أشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يحتاج المرضى الذين يعانون من ضعف جهاز المناعة أو أولئك المصابون بحالات صعبة من العدوى إلى علاج طويل الأمد لمنع عودة العدوى مرة أخرى.&nbsp; يمكن أن يتم تحويلك من نظام العلاج بالتسريب عبر الوريد إلى العلاج بالأقراص بمجرد تحسن حالتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المفترض ألا تتعرض لأي آثار عندما يقوم طبيبك بإيقاف العلاج بفيفند.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة إضافية بشأن استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي أو الممرضة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <table dir="rtl" border="1" cellspacing="0" cellpadding="0" align="right" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، إلا أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا حدثت أي آثار جانبية، فمن المرجح أن يكون أغلبها طفيفًا ومؤقتًا. وبالرغم من ذلك، فقد يكون بعضها خطيرًا ويستلزم رعاية طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الخطيرة &ndash; توقف عن تناول فيفند وقم بزيارة أحد الأطباء فورًا</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليرقان؛ وجود تغيرات في نتائج فحوصات الدم الخاصة بوظائف الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الأخرى</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">شائعة جدًا: قد تصيب أكثر من شخص واحد من بين كل ١٠ أشخاص</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>-</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخلل البصري (تغير في الرؤية يتضمن تغيم الرؤية، تغيرات في رؤية الألوان، عدم تحمل غير طبيعي للإدراك البصري للضوء، عمى الألوان، اضطرابات العينين، رؤية هالات ضوئية، العمى الليلي، تذبذب الرؤية، رؤية ومضات، الأورة البصرية، انخفاض حدة البصر، سطوع الرؤية، فقدان جزء من مجال الرؤية المعتاد، ظهور بقع أمام العينين)</p><p dir="RTL"><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى<br /><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي<br /><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان، القيء، الإسهال<br /><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع<br /><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الأطراف<br /><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المعدة</p><p dir="RTL"><strong>-</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات في التنفس</p><p dir="RTL"><strong>-</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات إنزيمات الكبد</p><p dir="RTL">&nbsp;</p><p dir="RTL">شائعة: قد تصيب ما يصل إلى شخص واحد من بين كل ١٠ أشخاص</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجيوب الأنفية، التهاب اللثة، القشعريرة، الضعف</p><p dir="RTL"><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانخفاض، بما في ذلك الانخفاض الشديد، في أعداد بعض أنواع خلايا الدم الحمراء (يكون ذا صلة بالمناعة في بعض الأحيان) و/أو البيضاء (يكون مصحوبًا بحمى في بعض الأحيان)، انخفاض أعداد خلايا تسمى الصفائح الدموية وهي تساعد الدم على التخثر</p><p dir="RTL"><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى السكر في الدم، انخفاض مستوى البوتاسيوم في الدم، انخفاض مستوى الصوديوم في الدم</p><p dir="RTL"><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق، الاكتئاب، الارتباك، التهيج، عدم القدرة على النوم، الهلاوس</p><p dir="RTL"><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات، الرعاش أو الحركات العضلية التي لا يمكن التحكم بها، الشعور بالوخز أو بإحساس غير طبيعي بالجلد، زيادة التوتر العضلي، النعاس، الدوار</p><p dir="RTL"><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود نزيف في العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في ضربات القلب، بما في ذلك التسارع الشديد في ضربات القلب، التباطؤ الشديد في ضربات القلب، الإغماء</p><p dir="RTL"><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم، التهاب أحد الأوردة (قد يصاحبه تكون جلطة دموية)</p><p dir="RTL"><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة حادة في التنفس، ألم الصدر، تورم الوجه (الفم، والشفتين، وحول العينين)، تراكم السوائل في الرئتين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك، عسر الهضم، التهاب الشفتين</p><p dir="RTL"><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليرقان، التهاب الكبد وإصابة الكبد</p><p dir="RTL"><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات طفح جلدي قد تؤدي إلى تبثر وتقشر شديد في الجلد يتسم بوجود منطقة مسطحة حمراء</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; على الجلد تغطيها نتوءات متقارنة صغيرة، احمرار الجلد</p><p dir="RTL"><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة</p><p dir="RTL"><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر<br /><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الظهر<br /><strong>-</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل الكلى، وجود دم في البول، وجود تغيرات في نتائج اختبارات وظائف الكلى</p><p dir="RTL">- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حروق الشمس أو تفاعلات جلدية شديدة بعد التعرض للضوء أو الشمس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الجلد</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير شائعة: قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠ شخص</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض شبيهة بالإنفلونزا، تهيج والتهاب القناة المعدية المعوية، التهاب القناة المعدية المعوية المسبب للإسهال المرتبط بالمضادات الحيوية، التهاب الأوعية الليمفاوية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب النسيج الرقيق الذي يبطن الجدار الداخلي للبطن ويغطي الأعضاء الموجودة في البطن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الغدد الليمفاوية (يكون مؤلمًا في بعض الأحيان)، فشل نخاع العظم المكوّن لخلايا الدم، زيادة اليوزينيات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تثبيط وظيفة الغدة الكظرية، قلة نشاط الغدة الدرقية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب وظائف الدماغ، أعراض مشابهة لمرض باركنسون، إصابة الأعصاب التي ينتج عنها الخدر، أو الألم، &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو الشعور بالوخز، أو الحرقان في اليدين أو القدمين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في التوازن أو التناسق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الدماغ&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ازدواج الرؤية، الحالات الخطيرة التي تصيب العينين بما في ذلك: ألم والتهاب العينين والجفون، اضطراب حركة العين، تلف العصب البصري الذي ينتج عنه خلل في الرؤية، تورم القرص البصري</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الحساسية للمس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب حس التذوق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات في السمع، طنين في الأذنين، الدوخة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب بعض الأعضاء الداخلية- البنكرياس والاثني عشر، تورم والتهاب اللسان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الكبد، فشل الكبد، مرض المرارة، حصوات المرارة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل، التهاب الأوردة تحت الجلد (قد يصاحبه &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكون جلطة دموية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكلى، وجود بروتينات في البول، تلف الكلى&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التسارع الشديد في معدل نبضات القلب أو تخطي ضربات قلب، وفي بعض الأحيان يكون مصحوبًا بنبضات كهربائية غير منتظمة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود نتائج غير طبيعية لرسم القلب (ECG)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى الكولستيرول في الدم، زيادة مستوى اليوريا في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية جلدية (شديدة أحيانًا)، بما في ذلك حالة جلدية مهددة للحياة تسبب &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بثورًا وتقرحات مؤلمة في الجلد والأغشية المخاطية، خاصة في الفم،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجلد، الشرى، احمرار الجلد وتهيجه، تغير لون الجلد إلى الأحمر أو الأرجواني الذي قد يسببه انخفاض تعداد الصفائح الدموية، الإكزيما</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات موضع التسريب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية أو استجابة مناعية مبالغة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب النسيج المحيط بالعظام</p><p dir="RTL">&nbsp;</p><p dir="RTL">نادرة: قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠٠ شخص</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط نشاط الغدة الدرقية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدهور وظائف الدماغ وهو إحدى المضاعفات الخطيرة لمرض الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان معظم الألياف في العصب البصري، تغيم القرنية، حركة العين بصورة لا إرادية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية الفقاعية للضوء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب يقوم فيه الجهاز المناعي للجسم بمهاجمة جزء من الجهاز العصبي الطرفي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في ضربات القلب أو في توصيل الإشارات القلبية (مهددة للحياة أحيانًا)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية مهدد للحياة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب نظام تخثر الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية جلدية (شديدة أحيانًا)، بما في ذلك الورم السريع (التورم) للأدمة والنسيج تحت الجلد والغشاء المخاطي والأنسجة تحت المخاطية، ظهور بقع جلدية حمراء سميكة مثيرة للحكة أو متقرحة ومصحوبة بقشور فضية بالجلد، تهيج الجلد والأغشية المخاطية، حالة جلدية مهددة للحياة تسبب انفصال أجزاء كبيرة من البشرة، وهي طبقة الجلد الخارجية، عن طبقات الجلد الموجودة أسفلها</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود بقع جلدية صغيرة جافة متقشرة، تكون سميكة أحيانًا وبها سنون مدببة أو &quot;نتوءات تشبه القرون&quot;</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية ذات معدل التكرار غير المعروف:</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النمش والبقع المصطبغة</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية المهمة الأخرى ذات معدل التكرار غير المعروف، ولكن ينبغي إبلاغها إلى طبيبك على الفور:</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود بقع حمراء متقشرة أو آفات جلدية على شكل حلقات قد تكون أحد أعراض مرض مناعة ذاتية يسمى لوباس إيريثماتوزس الجلدي</p><p dir="RTL">&nbsp;</p><p dir="RTL">حدثت حالات غير شائعة من التفاعلات أثناء التسريب عند استخدام فيفند (بما في ذلك الاحمرار، والحمى، والعرق، وزيادة معدل نبضات القلب، وضيق التنفس). قد يقوم طبيبك بإيقاف التسريب إذا حدثت هذه التفاعلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نظرًا لأنه من المعروف أن فيفند يؤثر على الكبد والكلى، ينبغي أن يقوم طبيبك بمراقبة وظائف كبدك وكليتيك عن طريق إجراء فحوصات للدم. يُرجى إخبار طبيبك إذا شعرت بأي آلام في المعدة أو إذا اختلفت درجة تماسك برازك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وردت تقارير عن حدوث حالات إصابة بسرطان الجلد لدى المرضى الذين خضعوا للعلاج بفيفند لفترات زمنية طويلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ظهرت حالات حروق الشمس أو التفاعلات الجلدية الشديدة بعد التعرض للضوء أو الشمس بمعدل أكثر تكرارًا لدى الأطفال. إذا أصبت أنت أو طفلك باضطرابات في الجلد، فقد يحيلك طبيبك إلى طبيب أمراض جلدية، الذي قد يقرر بعد الاستشارة أنه من المهم فحصك أو فحص طفلك بشكلٍ منتظم. لوحظ أيضًا ارتفاع مستويات إنزيمات الكبد بمعدل أكثر تكرارًا لدى الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا استمر أي من هذه الآثار الجانبية أو كان مزعجًا، يُرجى إخبار طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال الموحد: ١٩٩٩٩</p><ul><li dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</li><li dir="RTL">الموقع الإلكتروني:&nbsp;https://ade.sfda.gov.sa</li></ul></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>دول </strong><strong>الخليج</strong><strong> الأخرى:</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على الملصق. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر المذكور.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">صلاحية المستحضر ٣٦ شهر.<br />&nbsp;</p><p dir="RTL">ينبغي تخزين القارورة في درجة حرارة أقل من ٣٠ درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بمجرد تحضير فيفند، ينبغي استخدامه على الفور، ولكن إذا لزم الأمر، يمكن تخزينه لمدة تصل إلى ٢٤ ساعة في درجة حرارة تتراوح بين درجتين مئويتين و٨ درجات مئوية (في البراد (الثلاجة)). يجب أولًا تخفيف فيفند المحضَّر بأحد محاليل التسريب المتوافقة قبل أن يتم تسريبه. (يُرجى الرجوع إلى نهاية هذه النشرة للاطلاع على المزيد من المعلومات).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه التدابير على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي فوريكونازول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكون الآخر هو سلفوبوتيل إيثر بيتا سيكلودكسترين الصوديوم (انظر القسم ٢، يحتوي فيفند مسحوق ٢٠٠ ملجم لإعداد محلول التسريب على سيكلودكسترين والصوديوم).</p><p dir="RTL"><br />تحتوى كل قارورة على ٢٠٠ ملجم من فوريكونازول، بما يكافئ محلولًا بتركيز ١٠ ملجم/مل عندما يتم تحضيره<br />وفقًا لتوجيهات صيدلي أو ممرضة المستشفى الخاصة بك.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">يتم توفير فيفند في قوارير زجاجية مخصصة للاستخدام مرة واحدة، في صورة مسحوق لإعداد محلول للتسريب.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك </strong><strong>رخصة </strong><strong>التسويق</strong></p><p><strong>&nbsp;</strong>Pfizer Europe MA EEIG, Belgium.<br />&nbsp;</p><p dir="RTL"><strong>الشركة الصانعة </strong></p><p dir="RTL">Pharmacia &amp; Upjohn Company LLC, 7000 Portage Road Kalamazoo, MI 49001, United States</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر/تشرين الثاني ٢٠٢٣.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                VFEND 200 mg powder for solution for infusion 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 200 mg of voriconazole. 

After reconstitution each ml contains 10 mg of voriconazole. Once reconstituted further dilution is required before administration.

Excipients with known effect
Contain Sodium and cyclodextrins.

For the full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for infusion: White lyophilised powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>VFEND, is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:</p><p>&nbsp;</p><p>Treatment of invasive aspergillosis.</p><p>&nbsp;</p><p>Treatment of candidaemia in non-neutropenic patients.</p><p>&nbsp;</p><p>Treatment of fluconazole-resistant serious invasive <em>Candida</em> infections (including <em>C. krusei</em>).</p><p>&nbsp;</p><p>Treatment of serious fungal infections caused by <em>Scedosporium</em> spp. and <em>Fusarium</em> spp.</p><p>&nbsp;</p><p>VFEND should be administered primarily to patients with progressive, possibly life-threatening infections.</p><p>&nbsp;</p><p>Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Electrolyte disturbances such as hypokalaemia, hypomagnesaemia and hypocalcaemia should be monitored and corrected, if necessary, prior to initiation and during voriconazole therapy (see section 4.4).</p><p>&nbsp;</p><p>It is recommended that VFEND is administered at a maximum rate of 3&nbsp;mg/kg per hour over 1 to 3 hours.</p><p>&nbsp;</p><p>VFEND is also available as 50&nbsp;mg and 200&nbsp;mg film-coated tablets and 40&nbsp;mg/ml powder for oral suspension.</p><p>&nbsp;</p><p><u>Treatment</u></p><p><em>Adults </em></p><p>Therapy must be initiated with the specified loading dose regimen of either intravenous or oral VFEND to achieve plasma concentrations on Day 1 that are close to steady state. On the basis of the high oral bioavailability (96%; see section 5.2), switching between intravenous and oral administration is appropriate when clinically indicated.</p><p>&nbsp;</p><p>Detailed information on dosage recommendations is provided in the following table:</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p><strong>Intravenous </strong></p></td><td colspan="2"><p><strong>Oral </strong></p></td></tr><tr><td style="vertical-align:top"><p>Patients 40 kg and above*</p></td><td style="vertical-align:top"><p>Patients less than 40&nbsp;kg*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Loading dose regimen </strong></p><p><strong>(first 24 hours) </strong></p></td><td style="vertical-align:top"><p>6&nbsp;mg/kg every 12 hours</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>400&nbsp;mg every 12 hours</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>200&nbsp;mg every 12 hours</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Maintenance dose (after first 24 hours) </strong></p></td><td style="vertical-align:top"><p>4&nbsp;mg/kg twice daily</p></td><td style="vertical-align:top"><p>200&nbsp;mg twice daily</p></td><td style="vertical-align:top"><p>100&nbsp;mg twice daily</p></td></tr></tbody></table><p>* This also applies to patients aged 15 years and older</p><p>&nbsp;</p><p><em><u>Duration of treatment</u></em></p><p>Treatment duration should be as short as possible depending on the patient&rsquo;s clinical and mycological response. Long term exposure to voriconazole greater than 180 days (6 months) requires careful assessment of the benefit-risk balance (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p><em><u>Dosage adjustment (Adults)</u></em><em> </em></p><p>If patient is unable to tolerate intravenous treatment at 4&nbsp;mg/kg twice daily, reduce the dose to 3&nbsp;mg/kg twice daily.</p><p>&nbsp;</p><p>If patient response to treatment is inadequate, the maintenance dose may be increased to 300 mg twice daily for oral administration. For patients less than 40 kg the oral dose may be increased to 150 mg twice daily.</p><p>&nbsp;</p><p>If patient is unable to tolerate treatment at a higher dose reduce the oral dose by 50 mg steps to the 200 mg twice daily (or 100 mg twice daily for patients less than 40 kg) maintenance dose.</p><p>&nbsp;</p><p>In case of use as prophylaxis, refer below.</p><p>&nbsp;</p><p><em>Children (2 to &lt;12 years) and young adolescents with low body weight (12 to 14 years and &lt;50 kg)</em></p><p>Voriconazole should be dosed as children as these young adolescents may metabolise voriconazole more similarly to children than to adults.</p><p>&nbsp;</p><p>The recommended dosing regimen is as follows:</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td><p><strong>Intravenous </strong></p></td><td><p><strong>Oral</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Loading Dose Regimen</strong></p><p><strong>(first 24 hours)</strong></p></td><td style="vertical-align:top"><p>9&nbsp;mg/kg every 12 hours</p></td><td style="vertical-align:top"><p>Not recommended</p></td></tr><tr><td><p><strong>Maintenance Dose</strong></p><p><strong>(after first 24 hours)</strong></p></td><td><p>8&nbsp;mg/kg twice daily</p></td><td style="vertical-align:top"><p>9&nbsp;mg/kg twice daily<br />(a maximum dose of 350 mg twice daily)</p></td></tr></tbody></table><p>Note: Based on a population pharmacokinetic analysis in 112 immunocompromised paediatric patients aged 2 to &lt;12 years and 26 immunocompromised adolescents aged 12 to &lt;17 years.</p><p>&nbsp;</p><p>It is recommended to initiate the therapy with intravenous regimen, and oral regimen should be considered only after there is a significant clinical improvement. It should be noted that an 8&nbsp;mg/kg intravenous dose will provide voriconazole exposure approximately 2-fold higher than a 9&nbsp;mg/kg oral dose.</p><p>&nbsp;</p><p><em>All other adolescents (12 to 14 years and &ge;50 kg; 15 to 17 years regardless of body weight)</em></p><p>Voriconazole should be dosed as adults.</p><p>&nbsp;</p><p><em><u>Dosage adjustment (</u></em><em><u>Children [2 to &lt;12 years] and young adolescents with low body weight [12 to 14 years and &lt;50&nbsp;kg])</u></em></p><p>If patient response to treatment is inadequate, the intravenous dose may be increased by 1&nbsp;mg/kg steps. If patient is unable to tolerate treatment, reduce the intravenous dose by 1&nbsp;mg/kg steps.</p><p><em>&nbsp;</em></p><p>Use in paediatric patients aged 2 to &lt;12 years with hepatic or renal insufficiency has not been studied (see sections 4.8 and 5.2).</p><p><em>&nbsp;</em></p><p><u>Prophylaxis in Adults and Children</u></p><p>Prophylaxis should be initiated on the day of transplant and may be administered for up to 100 days. Prophylaxis should be as short as possible depending on the risk for developing invasive fungal infection (IFI) as defined by neutropenia or immunosuppression. It may only be continued up to 180 days after transplantation in case of continuing immunosuppression or graft versus host disease (GvHD) (see section 5.1).</p><p>&nbsp;</p><p><em>Dosage </em></p><p>The recommended dosing regimen for prophylaxis is the same as for treatment in the respective age groups. Please refer to the treatment tables above.</p><p>&nbsp;</p><p><em>Duration of prophylaxis</em></p><p>The safety and efficacy of voriconazole use for longer than 180 days has not been adequately studied in clinical trials.</p><p>&nbsp;</p><p>Use of voriconazole in prophylaxis for greater than 180 days (6 months) requires careful assessment of the benefit-risk balance (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p><u>The following instructions apply to both Treatment and Prophylaxis</u></p><p>&nbsp;</p><p><em>Dosage adjustment</em></p><p>For prophylaxis use, dose adjustments are not recommended in the case of lack of efficacy or treatment-related adverse events. In the case of treatment-related adverse events, discontinuation of voriconazole and use of alternative antifungal agents must be considered (see section 4.4 and 4.8)</p><p>&nbsp;</p><p><em><u>Dosage adjustments in case of coadministration</u></em></p><p>Rifabutin or phenytoin may be coadministered with voriconazole if the maintenance dose of voriconazole is increased to 5&nbsp;mg/kg intravenously twice daily, see sections 4.4 and 4.5.</p><p>&nbsp;</p><p>Efavirenz may be coadministered with voriconazole if the maintenance dose of voriconazole is increased to 400&nbsp;mg every 12 hours and the efavirenz dose is reduced by 50%, i.e. to 300&nbsp;mg once daily. When treatment with voriconazole is stopped, the initial dosage of efavirenz should be restored (see sections 4.4 and 4.5).</p><p>&nbsp;</p><p><em><u>Elderly</u></em></p><p>No dose adjustment is necessary for elderly patients (see section 5.2).</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p>In patients with moderate to severe renal dysfunction (creatinine clearance &lt; 50&nbsp;ml/min), accumulation of the intravenous vehicle, SBECD, occurs. Oral voriconazole should be administered to these patients, unless an assessment of the risk benefit to the patient justifies the use of intravenous voriconazole. Serum creatinine levels should be closely monitored in these patients and, if increases occur, consideration should be given to changing to oral voriconazole therapy (see section 5.2).</p><p>&nbsp;</p><p>Voriconazole is haemodialysed with a clearance of 121&nbsp;ml/min. A 4-hour haemodialysis session does not remove a sufficient amount of voriconazole to warrant dose adjustment.</p><p>&nbsp;</p><p>The intravenous vehicle, SBECD, is haemodialysed with a clearance of 55&nbsp;ml/min.</p><p><u>&nbsp;</u></p><p><em><u>Hepatic impairment</u></em></p><p>It is recommended that the standard loading dose regimens be used but that the maintenance dose be halved in patients with mild to moderate hepatic cirrhosis (Child-Pugh A and B) receiving voriconazole (see section 5.2).</p><p>&nbsp;</p><p>Voriconazole has not been studied in patients with severe chronic hepatic cirrhosis (Child-Pugh C).</p><p>&nbsp;</p><p>There is limited data on the safety of VFEND in patients with abnormal liver function tests (aspartate transaminase [AST], alanine transaminase [ALT], alkaline phosphatase [ALP], or total bilirubin &gt;5 times the upper limit of normal).</p><p>&nbsp;</p><p>Voriconazole has been associated with elevations in liver function tests and clinical signs of liver damage, such as jaundice, and must only be used in patients with severe hepatic impairment if the benefit outweighs the potential risk. Patients with severe hepatic impairment must be carefully monitored for drug toxicity (see section 4.8).</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>The safety and efficacy of VFEND in children below 2 years has not been established. Currently available data are described in sections 4.8 and 5.1 but no recommendation on a posology can be made.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>VFEND requires reconstitution and dilution (see section 6.6) prior to administration as an intravenous infusion. Not for bolus injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Coadministration with CYP3A4 substrates, terfenadine, astemizole, cisapride, pimozide, quinidine or ivabradine since increased plasma concentrations of these medicinal products can lead to QTc prolongation and rare occurrences of torsades de pointes (see section 4.5). 

Coadministration with rifampicin, carbamazepine, phenobarbital and St John’s Wort since these medicinal products are likely to decrease plasma voriconazole concentrations significantly (see section 4.5). 

Coadministration of standard doses of voriconazole with efavirenz doses of 400 mg once daily or higher is contraindicated, because efavirenz significantly decreases plasma voriconazole concentrations in healthy subjects at these doses. Voriconazole also significantly increases efavirenz plasma concentrations (see section 4.5, for lower doses see section 4.4).

Coadministration with high-dose ritonavir (400 mg and above twice daily) because ritonavir significantly decreases plasma voriconazole concentrations in healthy subjects at this dose (see section 4.5, for lower doses see section 4.4). 

Coadministration with ergot alkaloids (ergotamine, dihydroergotamine), which are CYP3A4 substrates, since increased plasma concentrations of these medicinal products can lead to ergotism (see section 4.5). 

Coadministration with sirolimus since voriconazole is likely to increase plasma concentrations of sirolimus significantly (see section 4.5). 

Coadministration of voriconazole with naloxegol, a CYP3A4 substrate, since increased plasma concentrations of naloxegol can precipitate opioid withdrawal symptoms (see section 4.5).

Coadministration of voriconazole with tolvaptan since strong CYP3A4 inhibitors such as voriconazole significantly increase plasma concentrations of tolvaptan (see section 4.5).

Coadministration of voriconazole with lurasidone since significant increases in lurasidone exposure have the potential for serious adverse reactions (see section 4.5).

Coadministration with venetoclax at initiation and during venetoclax dose titration phase since voriconazole is likely to significantly increase plasma concentrations of venetoclax and increase risk of tumour lysis syndrome (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p><u>Hypersensitivity</u></p><p>Caution should be used in prescribing VFEND to patients with hypersensitivity to other azoles (see also section 4.8).</p><p>&nbsp;</p><p><u>Duration of treatment</u></p><p>The duration of treatment with the intravenous formulation should be no longer than 6 months (see section 5.3).</p><p>&nbsp;</p><p><u>Cardiovascular</u></p><p>Voriconazole has been associated with QTc interval prolongation. There have been rare cases of torsades de pointes in patients taking voriconazole who had risk factors, such as history of cardiotoxic chemotherapy, cardiomyopathy, hypokalaemia and concomitant medicinal products that may have been contributory. Voriconazole should be administered with caution to patients with potentially proarrhythmic conditions, such as:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Congenital or acquired QTc prolongation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiomyopathy, in particular when heart failure is present.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sinus bradycardia.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Existing symptomatic arrhythmias.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Concomitant medicinal product that is known to prolong QTc interval. Electrolyte disturbances such as hypokalaemia, hypomagnesaemia and hypocalcaemia should be monitored and corrected, if necessary, prior to initiation and during voriconazole therapy (see section 4.2). A study has been conducted in healthy volunteers which examined the effect on QTc interval of single doses of voriconazole up to 4 times the usual daily dose. No subject experienced an interval exceeding the potentially clinically-relevant threshold of 500 msec (see section 5.1).</p><p>&nbsp;</p><p><u>Infusion-related reactions</u></p><p>Infusion-related reactions, predominantly flushing and nausea, have been observed during administration of the intravenous formulation of voriconazole. Depending on the severity of symptoms, consideration should be given to stopping treatment (see section 4.8).</p><p>&nbsp;</p><p><u>Hepatic toxicity</u></p><p>In clinical trials, there have been cases of serious hepatic reactions during treatment with voriconazole (including clinical hepatitis, cholestasis and fulminant hepatic failure, including fatalities). Instances of hepatic reactions were noted to occur primarily in patients with serious underlying medical conditions (predominantly haematological malignancy). Transient hepatic reactions, including hepatitis and jaundice, have occurred among patients with no other identifiable risk factors. Liver dysfunction has usually been reversible on discontinuation of therapy (see section 4.8).</p><p>&nbsp;</p><p><u>Monitoring of hepatic function</u></p><p>Patients receiving VFEND must be carefully monitored for hepatic toxicity. Clinical management should include laboratory evaluation of hepatic function (specifically AST and ALT) at the initiation of treatment with VFEND and at least weekly for the first month of treatment. Treatment duration should be as short as possible; however, if based on the benefit-risk assessment the treatment is continued (see section 4.2), monitoring frequency can be reduced to monthly if there are no changes in the liver function tests.</p><p>&nbsp;</p><p>If the liver function tests become markedly elevated, VFEND should be discontinued, unless the medical judgment of the risk-benefit of the treatment for the patient justifies continued use.</p><p>&nbsp;</p><p>Monitoring of hepatic function should be carried out in both children and adults.</p><p>&nbsp;</p><p><u>Serious dermatological adverse reactions</u></p><p><u>&nbsp;</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Phototoxicity</u></p><p>In addition VFEND has been associated with phototoxicity including reactions such as ephelides, lentigo, actinic keratosis and pseudoporphyria. There is a potential increased risk of skin reactions/toxicity with concomitant use of photosensitising agents (e.g., methotrexate, etc). It is recommended that all patients, including children, avoid exposure to direct sunlight during VFEND treatment and use measures such as protective clothing and sunscreen with high sun protection factor (SPF). In addition, VFEND has been associated with photosensitivity related skin reactions such as cheilitis, and cutaneous lupus erythematosus, as well as increased risk of skin toxicity with concomitant use of methotrexate, a drug associated with ultraviolet (UV) reactivation. There is the potential for this risk to be observed with other drugs associated with UV reactivation.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Squamous cell carcinoma of the skin (SCC)</u></p><p>Squamous cell carcinoma of the skin (including cutaneous SCC in situ, or Bowen&rsquo;s disease) has been reported in patients, some of whom have reported prior phototoxic reactions. If phototoxic reactions occur multidisciplinary advice should be sought, VFEND discontinuation and use of alternative antifungal agents should be considered and the patient should be referred to a dermatologist. If VFEND is continued, however, dermatologic evaluation should be performed on a systematic and regular basis, to allow early detection and management of premalignant lesions. VFEND should be discontinued if premalignant skin lesions or squamous cell carcinoma are identified (see below the section under Long-term treatment).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Severe cutaneous adverse reactions</u></p><p>Severe cutaneous adverse<u> </u>reactions (SCARs) including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS), which can be life-threatening or fatal, have been reported with the use of voriconazole. If a patient develops a rash he should be monitored closely and VFEND discontinued if lesions progress.</p><p>&nbsp;</p><p><u>Adrenal events</u></p><p>Reversible cases of adrenal insufficiency have been reported in patients receiving azoles, including: voriconazole. Adrenal insufficiency has been reported in patients receiving azoles with or without concomitant corticosteroids. In patients receiving azoles without corticosteroids, adrenal insufficiency is related to direct inhibition of steroidogenesis by azoles. In patients taking corticosteroids, voriconazole associated CYP3A4 inhibition of their metabolism may lead to corticosteroid excess and adrenal suppression (see section 4.5). Cushing&rsquo;s syndrome with and without subsequent adrenal insufficiency has also been reported in patients receiving voriconazole concomitantly with corticosteroids.</p><p>&nbsp;</p><p>Patients on long-term treatment with voriconazole and corticosteroids (including inhaled corticosteroids e.g., budesonide and intranasal corticosteroids) should be carefully monitored for adrenal cortex dysfunction both during treatment and when voriconazole is discontinued (see section 4.5). Patients should be instructed to seek immediate medical care if they develop signs and symptoms of Cushing&rsquo;s syndrome or adrenal insufficiency.</p><p>&nbsp;</p><p><u>Long-term treatment</u></p><p>Long term exposure (treatment or prophylaxis) greater than 180 days (6 months) requires careful assessment of the benefit-risk balance and physicians should therefore consider the need to limit the exposure to VFEND (see sections 4.2 and 5.1).</p><p>&nbsp;</p><p>Squamous cell carcinoma of the skin (SCC) (including cutaneous SCC in situ, or Bowen&rsquo;s disease) has been reported in relation with long-term VFEND treatment (see section 4.8).</p><p>&nbsp;</p><p>Non-infectious periostitis with elevated fluoride and alkaline phosphatase levels has been reported in transplant patients. If a patient develops skeletal pain and radiologic findings compatible with periostitis VFEND discontinuation should be considered after multidisciplinary advice (see section 4.8).</p><p>&nbsp;</p><p><u>Visual adverse reactions</u></p><p>There have been reports of prolonged visual adverse reactions, including blurred vision, optic neuritis and papilloedema (see section 4.8).</p><p>&nbsp;</p><p><u>Renal adverse reactions</u></p><p>Acute renal failure has been observed in severely ill patients undergoing treatment with VFEND. Patients being treated with voriconazole are likely to be treated concomitantly with nephrotoxic medicinal products and have concurrent conditions that may result in decreased renal function (see section 4.8).</p><p>&nbsp;</p><p><u>Monitoring of renal function</u></p><p>Patients should be monitored for the development of abnormal renal function. This should include laboratory evaluation, particularly serum creatinine.</p><p>&nbsp;</p><p><u>Monitoring of pancreatic function</u></p><p>Patients, especially children, with risk factors for acute pancreatitis (e.g., recent chemotherapy, haematopoietic stem cell transplantation [HSCT]), should be monitored closely during VFEND treatment. Monitoring of serum amylase or lipase may be considered in this clinical situation.</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>Safety and effectiveness in paediatric subjects below the age of two years has not been established (see sections 4.8 and 5.1). Voriconazole is indicated for paediatric patients aged two years or older. A higher frequency of liver enzyme elevations was observed in the paediatric population (see section 4.8). Hepatic function should be monitored in both children and adults. Oral bioavailability may be limited in paediatric patients aged 2 to &lt;12 years with malabsorption and very low body weight for age. In that case, intravenous voriconazole administration is recommended.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Serious dermatological adverse reactions (including SCC)</u></p><p>The frequency of phototoxicity reactions is higher in the paediatric population. As an evolution towards SCC has been reported, stringent measures for the photoprotection are warranted in this population of patients. In children experiencing photoaging injuries such as lentigines or ephelides, sun avoidance and dermatologic follow-up are recommended even after treatment discontinuation.</p><p>&nbsp;</p><p><u>Prophylaxis</u></p><p>In case of treatment-related adverse events (hepatotoxicity, severe skin reactions including phototoxicity and SCC, severe or prolonged visual disorders and periostitis), discontinuation of voriconazole and use of alternative antifungal agents must be considered.</p><p>&nbsp;</p><p><u>Phenytoin (CYP2C9 substrate and potent CYP450 inducer)</u></p><p>Careful monitoring of phenytoin levels is recommended when phenytoin is coadministered with voriconazole. Concomitant use of voriconazole and phenytoin should be avoided unless the benefit outweighs the risk (see section 4.5).</p><p>&nbsp;</p><p><u>Efavirenz (CYP450 inducer; CYP3A4 inhibitor and substrate)</u></p><p>When voriconazole is coadministered with efavirenz the dose of voriconazole should be increased to 400&nbsp;mg every 12 hours and the dose of efavirenz should be decreased to 300&nbsp;mg every 24 hours (see sections 4.2, 4.3 and 4.5).</p><p>&nbsp;</p><p><u>Glasdegib<strong> </strong>(CYP3A4 substrate)</u></p><p>Coadministration of voriconazole is expected to increase glasdegib plasma concentrations and increase the risk of QTc prolongation (see section 4.5). If concomitant use cannot be avoided, frequent ECG monitoring is recommended.</p><p>&nbsp;</p><p><u>Tyrosine kinase inhibitors (CYP3A4 substrate)</u></p><p>Coadministration of voriconazole with tyrosine kinase inhibitors metabolised by CYP3A4 is expected to increase tyrosine kinase inhibitor plasma concentrations and the risk of adverse reactions. If concomitant use cannot be avoided, dose reduction of the tyrosine kinase inhibitor and close clinical monitoring is recommended (see section 4.5).</p><p>&nbsp;</p><p><u>Rifabutin (potent CYP450 inducer)</u></p><p>Careful monitoring of full blood counts and adverse reactions to rifabutin (e.g., uveitis) is recommended when rifabutin is coadministered with voriconazole. Concomitant use of voriconazole and rifabutin should be avoided unless the benefit outweighs the risk (see section 4.5).</p><p>&nbsp;</p><p><u>Ritonavir (potent CYP450 inducer; CYP3A4 inhibitor and substrate)</u></p><p>Coadministration of voriconazole and low-dose ritonavir (100&nbsp;mg twice daily) should be avoided unless an assessment of the benefit/risk to the patient justifies the use of voriconazole (see sections 4.3 and 4.5).</p><p>&nbsp;</p><p><u>Everolimus </u><u>(CYP3A4 substrate, P-gp substrate)</u></p><p>Coadministration of voriconazole with everolimus is not recommended because voriconazole is expected to significantly increase everolimus concentrations. Currently there are insufficient data to allow dosing recommendations in this situation (see section 4.5).</p><p>&nbsp;</p><p><u>Methadone (CYP3A4 substrate)</u></p><p>Frequent monitoring for adverse reactions and toxicity related to methadone, including QTc prolongation, is recommended when coadministered with voriconazole since methadone levels increased following coadministration of voriconazole. Dose reduction of methadone may be needed (see section 4.5).</p><p>&nbsp;</p><p><u>Short-acting opiates (CYP3A4 substrate)</u></p><p>Reduction in the dose of alfentanil, fentanyl and other short-acting opiates similar in structure to alfentanil and metabolised by CYP3A4 (e.g., sufentanil) should be considered when coadministered with voriconazole (see section 4.5). As the half-life of alfentanil is prolonged in a 4-fold manner when alfentanil is coadministered with voriconazole, and in an independent published study concomitant use of voriconazole with fentanyl resulted in an increase in the mean AUC<sub>0-&infin;</sub> of fentanyl, frequent monitoring for opiate‑associated adverse reactions (including a longer respiratory<em> </em>monitoring period) may be necessary.</p><p>&nbsp;</p><p><u>Long-acting opiates </u><u>(CYP3A4 substrate)</u></p><p>Reduction in the dose of oxycodone and other long-acting opiates metabolised by CYP3A4 (e.g., hydrocodone) should be considered when coadministered with voriconazole. Frequent monitoring for opiate‑associated adverse reactions may be necessary (see section 4.5).</p><p>&nbsp;</p><p><u>Fluconazole<em> </em>(CYP2C9, CYP2C19 and CYP3A4 inhibitor)</u></p><p>Coadministration of oral voriconazole and oral fluconazole resulted in a significant increase in C<sub>max</sub> and AUC<sub>&tau;</sub> of voriconazole in healthy subjects. The reduced dose and/or frequency of voriconazole and fluconazole that would eliminate this effect have not been established. Monitoring for voriconazole‑associated adverse reactions is recommended if voriconazole is used sequentially after fluconazole (see section 4.5).</p><p>&nbsp;</p><p><u>Excipients</u></p><p>&nbsp;</p><p><em><u>Sodium</u></em></p><p>This medicinal product contains Sodium.</p><p>&nbsp;</p><p><em><u>Cyclodextrins</u></em><em><u> </u></em></p><p>The powder for solution for infusion contains cyclodextrins, which can influence the properties (such as toxicity) of the active substance and other medicines. Safety aspects of cyclodextrins have been considered during the development and safety assessment of the drug product.</p><p>&nbsp;</p><p>As cyclodextrins are renally excreted, in patients with moderate to severe renal dysfunction accumulation of cyclodextrin may occur.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Voriconazole is metabolised by, and inhibits the activity of, cytochrome P450 isoenzymes, CYP2C19, CYP2C9, and CYP3A4. Inhibitors or inducers of these isoenzymes may increase or decrease voriconazole plasma concentrations, respectively, and there is potential for voriconazole to increase the plasma concentrations of substances metabolised by these CYP450 isoenzymes, in particular for substances metabolised by CYP3A4 since voriconazole is a strong CYP3A4 inhibitor though the increase in AUC is substrate dependent (see Table below).</p><p>&nbsp;</p><p>Unless otherwise specified, drug interaction studies have been performed in healthy adult male subjects using multiple dosing to steady state with oral voriconazole at 200 mg twice daily (BID). These results are relevant to other populations and routes of administration.</p><p>&nbsp;</p><p>Voriconazole should be administered with caution in patients with concomitant medication that is known to prolong QTc interval. When there is also a potential for voriconazole to increase the plasma concentrations of substances metabolised by CYP3A4 isoenzymes (certain antihistamines, quinidine, cisapride, pimozide and ivabradine), coadministration is contraindicated (see below and section 4.3).</p><p>&nbsp;</p><p><u>Interaction table</u></p><p>Interactions between voriconazole and other medicinal products are listed in the table below (once daily as &ldquo;QD&rdquo;, twice daily as &ldquo;BID&rdquo;, three times daily as &ldquo;TID&rdquo; and not determined as &ldquo;ND&rdquo;). The direction of the arrow for each pharmacokinetic parameter is based on the 90% confidence interval of the geometric mean ratio being within (&harr;), below (&darr;) or above (&uarr;) the 80-125% range. The asterisk (*) indicates a two-way interaction. AUC<sub>t</sub>, AUC<sub>t</sub> and AUC<sub>0-</sub><sub>&yen;</sub> represent area under the curve over a dosing interval, from time zero to the time with detectable measurement and from time zero to infinity, respectively.</p><p>&nbsp;</p><p>The interactions in the table are presented in the following order: contraindications, those requiring dose adjustment and careful clinical and/or biological monitoring, and finally those that have no significant pharmacokinetic interaction but may be of clinical interest in this therapeutic field.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top">&nbsp;<p><strong>Medicinal product<br /><em>[Mechanism of interaction]</em></strong></p></td><td style="vertical-align:top"><p><strong>Interaction<br />Geometric mean changes (%)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations concerning<br />coadministration</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Astemizole, cisapride, pimozide, quinidine, terfenadine and ivabradine</p><p><em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>Although not studied, increased plasma concentrations of these medicinal products can lead to QTc prolongation and rare occurrences of torsades de pointes.</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Contraindicated</strong> (see section 4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Carbamazepine and long-acting barbiturates (including but not limited to: phenobarbital, mephobarbital)<br /><em>[potent CYP450 inducers]</em></p></td><td style="vertical-align:top"><p>Although not studied, carbamazepine and long-acting barbiturates are likely to significantly decrease plasma voriconazole concentrations.</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Contraindicated</strong> (see section 4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Efavirenz (a non-nucleoside reverse transcriptase inhibitor) <em>[CYP450 inducer; CYP3A4 inhibitor and substrate]</em></p><p><em>&nbsp;</em></p><p>Efavirenz 400&nbsp;mg QD, coadministered with voriconazole 200 mg BID<sup>*</sup></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Efavirenz 300&nbsp;mg QD, coadministered with voriconazole 400&nbsp;mg BID<sup>*</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Efavirenz C<sub>max</sub> &shy; 38%<br />Efavirenz AUCt &shy; 44%</p><p>Voriconazole C<sub>max</sub> &macr; 61%<br />Voriconazole AUCt &macr; 77%</p><p>&nbsp;</p><p>&nbsp;</p><p>Compared to efavirenz 600 mg QD,</p><p>Efavirenz C<sub>max</sub> &harr;<br />Efavirenz AUCt &shy; 17%<br />&nbsp;</p><p>Compared to voriconazole 200&nbsp;mg BID,</p><p>Voriconazole C<sub>max</sub> &shy; 23%<br />Voriconazole AUCt &macr; 7%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Use of standard doses of voriconazole with efavirenz doses of 400&nbsp;mg QD or higher is <strong>contraindicated</strong> (see section 4.3).</p><p>&nbsp;</p><p>Voriconazole may be coadministered with efavirenz if the voriconazole maintenance dose is increased to 400&nbsp;mg BID and the efavirenz dose is decreased to 300&nbsp;mg QD. When voriconazole treatment is stopped, the initial dose of efavirenz should be restored (see sections 4.2 and 4.4).</p></td></tr><tr><td style="vertical-align:top"><p>Ergot alkaloids (including but not limited to: ergotamine and dihydroergotamine)<br /><em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to increase the plasma concentrations of ergot alkaloids and lead to ergotism.</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Contraindicated</strong> (see section 4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Lurasidone</p><p><em>[CYP3A4 substrate]</em></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to significantly increase the plasma concentrations of lurasidone</p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong> (see section 4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Naloxegol</p><p><em>[CYP3A4 substrate]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to significantly increase the plasma concentrations of naloxegol</p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong> (see section 4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Rifabutin</p><p><em>[potent CYP450 inducer]</em></p><p>&nbsp;</p><p>300&nbsp;mg QD</p><p>&nbsp;</p><p>&nbsp;</p><p>300&nbsp;mg QD (coadministered with voriconazole 350&nbsp;mg BID)<sup>*</sup></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>300&nbsp;mg QD (coadministered with voriconazole 400&nbsp;mg BID)<sup>*</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Voriconazole C<sub>max</sub> &macr; 69%<br />Voriconazole AUCt &macr; 78%</p><p>&nbsp;</p><p>Compared to voriconazole 200 mg BID,</p><p>Voriconazole C<sub>max</sub> &macr; 4%<br />Voriconazole AUCt &macr; 32%</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Rifabutin C<sub>max</sub> &shy; 195%<br />Rifabutin AUCt &shy; 331%</p><p>Compared to voriconazole 200 mg BID,</p><p>Voriconazole C<sub>max</sub> &shy; 104%<br />Voriconazole AUCt &shy; 87%</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Concomitant use of voriconazole and rifabutin should be avoided unless the benefit outweighs the risk.</p><p>The maintenance dose of voriconazole may be increased to 5&nbsp;mg/kg intravenously BID or from 200&nbsp;mg to 350&nbsp;mg orally BID (100&nbsp;mg to 200&nbsp;mg orally BID in patients less than 40&nbsp;kg) (see section 4.2).</p><p>Careful monitoring of full blood counts and adverse reactions to rifabutin (e.g., uveitis) is recommended when rifabutin is coadministered with voriconazole.</p></td></tr><tr><td style="vertical-align:top"><p>Rifampicin (600&nbsp;mg QD)<br /><em>[potent CYP450 inducer]</em></p></td><td style="vertical-align:top"><p>Voriconazole C<sub>max</sub> &macr; 93%<br />Voriconazole AUCt &macr; 96%</p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong> (see section 4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Ritonavir (protease inhibitor)<br /><em>[potent CYP450 inducer; CYP3A4 inhibitor and substrate]</em><br />&nbsp;</p><p>High dose (400&nbsp;mg BID)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;Low dose (100&nbsp;mg BID)<sup>*</sup><br />&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Ritonavir C<sub>max</sub> and AUCt &harr;<br />Voriconazole C<sub>max</sub> &macr; 66%<br />Voriconazole AUCt &macr; 82%<br />&nbsp;</p><p>&nbsp;</p><p>Ritonavir C<sub>max</sub> &macr; 25%<br />Ritonavir AUCt &macr;13%<br />Voriconazole C<sub>max</sub> &macr; 24%<br />Voriconazole AUCt &macr; 39%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Coadministration of voriconazole and high doses of ritonavir (400&nbsp;mg and above BID) is <strong>contraindicated</strong> (see section 4.3).</p><p>&nbsp;</p><p>Coadministration of voriconazole and low-dose ritonavir (100&nbsp;mg BID) should be avoided unless an assessment of the benefit/risk to the patient justifies the use of voriconazole.</p></td></tr><tr><td style="vertical-align:top"><p>St. John&rsquo;s Wort</p><p><em>[CYP450 inducer; P-gp&nbsp;inducer]</em></p><p>300&nbsp;mg TID (coadministered with voriconazole 400&nbsp;mg single dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>In an independent published study,</p><p>Voriconazole AUC<sub>0-</sub><sub>&yen;</sub> &macr; 59%</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Contraindicated</strong> (see section 4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Tolvaptan</p><p><em>[CYP3A substrate]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to significantly increase the plasma concentrations of tolvaptan.</p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong> (see section 4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Venetoclax</p><p><em>[CYP3A substrate]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to significantly increase the plasma concentrations of venetoclax.</p></td><td style="vertical-align:top"><p>Concomitant administration of voriconazole is <strong>contraindicated</strong> at initiation and during venetoclax dose titration phase (see section 4.3). Dose reduction of venetoclax is required as instructed in venetoclax prescribing information during steady daily dosing; close monitoring for signs of toxicity is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Fluconazole (200&nbsp;mg QD)<br /><em>[CYP2C9, CYP2C19 and CYP3A4 inhibitor]</em></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Voriconazole C<sub>max</sub> &shy; 57%<br />Voriconazole AUCt &shy; 79%</p><p>Fluconazole C<sub>max</sub> ND<br />Fluconazole AUCt ND</p><p><br />&nbsp;</p></td><td style="vertical-align:top"><p>The reduced dose and/or frequency of voriconazole and fluconazole that would eliminate this effect have not been established. Monitoring for voriconazole-associated adverse reactions is recommended if voriconazole is used sequentially after fluconazole.</p></td></tr><tr><td style="vertical-align:top"><p>Phenytoin<br /><em>[CYP2C9 substrate and potent CYP450 inducer]</em></p><p><em>&nbsp;</em></p><p>300&nbsp;mg QD</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>300&nbsp;mg QD (coadministered with voriconazole 400&nbsp;mg BID)<sup>*</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Voriconazole C<sub>max</sub> &macr; 49%<br />Voriconazole AUCt &macr; 69%</p><p>&nbsp;</p><p>&nbsp;</p><p>Phenytoin C<sub>max</sub> &shy; 67%<br />Phenytoin AUCt &shy; 81%</p><p>Compared to voriconazole 200&nbsp;mg BID,</p><p>Voriconazole C<sub>max</sub> &shy; 34%<br />Voriconazole AUCt &shy; 39%</p></td><td style="vertical-align:top"><p>Concomitant use of voriconazole and phenytoin should be avoided unless the benefit outweighs the risk. Careful monitoring of phenytoin plasma levels is recommended.</p><p>&nbsp;</p><p>Phenytoin may be coadministered with voriconazole if the maintenance dose of voriconazole is increased to 5&nbsp;mg/kg IV BID or from 200&nbsp;mg to 400&nbsp;mg oral BID (100&nbsp;mg to 200&nbsp;mg oral BID in patients less than 40&nbsp;kg) (see section 4.2).</p></td></tr><tr><td style="vertical-align:top"><p>Letermovir</p><p><em>[CYP2C9 and CYP2C19 inducer]</em></p></td><td style="vertical-align:top"><p>Voriconazole C<sub>max</sub> &darr; 39%</p><p>Voriconazole AUC<sub>0-12</sub> &darr; 44%</p><p>Voriconazole C<sub>12</sub>&nbsp;&darr; 51%</p></td><td style="vertical-align:top"><p>If concomitant administration of voriconazole with letermovir cannot be avoided, monitor for loss of voriconazole effectiveness.</p></td></tr><tr><td style="vertical-align:top"><p>Flucloxacillin<br /><em>[CYP450 inducer]</em></p></td><td style="vertical-align:top"><p>Significantly decreased plasma voriconazole concentrations have been reported.</p></td><td style="vertical-align:top"><p>If concomitant administration of voriconazole with flucloxacillin cannot be avoided, monitor for potential loss of voriconazole effectiveness (e.g., by therapeutic drug monitoring); increasing the dose of voriconazole may be needed.</p></td></tr><tr><td style="vertical-align:top"><p>Glasdegib<br /><em>[CYP3A4 substrate]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to increase the plasma concentrations of glasdegib and increase risk of QTc prolongation.</p></td><td style="vertical-align:top"><p>If concomitant use cannot be avoided, frequent ECG monitoring is recommended (see section 4.4).</p></td></tr><tr><td style="vertical-align:top"><p>Tyrosine kinase inhibitors (including but not limited to: axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib)</p><p><em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole may increase plasma concentrations of tyrosine kinase inhibitors metabolised by CYP3A4.</p></td><td style="vertical-align:top"><p>If concomitant use cannot be avoided, dose reduction of the tyrosine kinase inhibitor and close clinical monitoring is recommended (see section 4.4).</p></td></tr><tr><td style="vertical-align:top"><p>Anticoagulants</p><p>&nbsp;</p><p>Warfarin (30&nbsp;mg single dose, coadministered with 300&nbsp;mg BID voriconazole)</p><p><em>[CYP2C9 substrate]</em></p><p><em>&nbsp;</em></p><p>Other oral coumarins<br />(including but not limited to: phenprocoumon, acenocoumarol)</p><p><em>[CYP2C9 and CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Maximum increase in prothrombin time was approximately 2-fold.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Although not studied, voriconazole may increase the plasma concentrations of coumarins that may cause an increase in prothrombin time.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Close monitoring of prothrombin time or other suitable anticoagulation tests is recommended, and the dose of anticoagulants should be adjusted accordingly.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ivacaftor</p><p><em>[CYP3A4 substrate]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to increase the plasma concentrations of ivacaftor with risk of increased adverse reactions.</p></td><td style="vertical-align:top"><p>Dose reduction of ivacaftor is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Benzodiazepines</p><p><em>[CYP3A4 substrates]</em></p><p>Midazolam (0.05 mg/kg IV single dose)</p><p>&nbsp;</p><p>Midazolam (7.5 mg oral single dose)</p><p>&nbsp;</p><p>&nbsp;</p><p>Other benzodiazepines (including but not limited to: triazolam, alprazolam)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>In an independent published study,</p><p>Midazolam AUC<sub>0-</sub><sub>&yen;</sub> &shy; 3.7-fold</p><p>&nbsp;</p><p>In an independent published study,</p><p>Midazolam C<sub>max</sub> &shy; 3.8-fold</p><p>Midazolam AUC<sub>0-</sub><sub>&yen;</sub> &shy; 10.3-fold</p><p>&nbsp;</p><p>Although not studied, voriconazole is likely to increase the plasma concentrations of other benzodiazepines that are metabolised by CYP3A4 and lead to a prolonged sedative effect.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Dose reduction of benzodiazepines should be considered.</p></td></tr><tr><td style="vertical-align:top"><p>Immunosuppressants</p><p><em>[CYP3A4 substrates]</em></p><p><em>&nbsp;</em></p><p>Sirolimus (2&nbsp;mg single dose)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Everolimus</p><p><em>[also P‑gp substrate]</em></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Ciclosporin (in stable renal transplant recipients receiving chronic ciclosporin therapy)<br />&nbsp;</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Tacrolimus (0.1&nbsp;mg/kg single dose)<br />&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>In an independent published study, Sirolimus C<sub>max</sub> &shy; 6.6-fold<br />Sirolimus AUC<sub>0-</sub><sub>&yen;</sub> &shy; 11-fold</p><p>&nbsp;</p><p>&nbsp;</p><p>Although not studied, voriconazole is likely to significantly increase the plasma concentrations of everolimus.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Ciclosporin C<sub>max</sub> &shy; 13%<br />Ciclosporin AUCt &shy; 70%</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Tacrolimus C<sub>max</sub> &shy; 117%<br />Tacrolimus AUC<sub>t</sub> &shy; 221%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Coadministration of voriconazole and sirolimus is <strong>contraindicated</strong> (see section 4.3).</p><p>&nbsp;</p><p>Coadministration of voriconazole and everolimus is not recommended because voriconazole is expected to significantly increase everolimus concentrations (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p>When initiating voriconazole in patients already on ciclosporin it is recommended that the ciclosporin dose be halved and ciclosporin level carefully monitored. Increased ciclosporin levels have been associated with nephrotoxicity. <u>When voriconazole is discontinued, ciclosporin levels must be carefully monitored and the dose increased as necessary</u>.</p><p>&nbsp;</p><p>When initiating voriconazole in patients already on tacrolimus, it is recommended that the tacrolimus dose be reduced to a third of the original dose and tacrolimus level carefully monitored. Increased tacrolimus levels have been associated with nephrotoxicity. <u>When voriconazole is discontinued, tacrolimus levels must be carefully monitored and the dose increased as necessary</u>.</p></td></tr><tr><td style="vertical-align:top"><p>Long-Acting Opiates</p><p><em>[CYP3A4 substrates]</em><br />&nbsp;</p><p>Oxycodone (10&nbsp;mg single dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>In an independent published study,</p><p>Oxycodone C<sub>max</sub> &shy; 1.7-fold<br />Oxycodone AUC<sub>0-</sub><sub>&yen;</sub> &shy; 3.6-fold<br />&nbsp;</p></td><td style="vertical-align:top"><p>Dose reduction in oxycodone and other long-acting opiates metabolised by CYP3A4 (e.g.,&nbsp;hydrocodone) should be considered. Frequent monitoring for opiate‑associated adverse reactions may be necessary.</p></td></tr><tr><td style="vertical-align:top"><p>Methadone (32-100&nbsp;mg QD)</p><p><em>[CYP3A4 substrate]</em></p></td><td style="vertical-align:top"><p>R-methadone (active) C<sub>max</sub> &shy; 31%<br />R-methadone (active) AUCt &shy; 47%<br />S-methadone C<sub>max</sub> &shy; 65%<br />S-methadone AUCt &shy; 103%</p></td><td style="vertical-align:top"><p>Frequent monitoring for adverse reactions and toxicity related to methadone, including QTc prolongation, is recommended. Dose reduction of methadone may be needed.</p></td></tr><tr><td style="vertical-align:top"><p>Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) <em>[CYP2C9 substrates]</em></p><p><em>&nbsp;</em></p><p>Ibuprofen (400&nbsp;mg single dose)</p><p>&nbsp;</p><p>Diclofenac (50&nbsp;mg single dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>S-Ibuprofen C<sub>max</sub> &shy; 20%<br />S-Ibuprofen AUC<sub>0-</sub><sub>&yen;</sub> &shy; 100%</p><p>&nbsp;</p><p>Diclofenac C<sub>max</sub> &shy; 114%<br />Diclofenac AUC<sub>0-</sub><sub>&yen;</sub> &shy; 78%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Frequent monitoring for adverse reactions and toxicity related to NSAIDs is recommended. Dose reduction of NSAIDs may be needed.</p></td></tr><tr><td style="vertical-align:top"><p>Omeprazole (40&nbsp;mg QD)<sup>*</sup><br /><em>[CYP2C19 inhibitor; CYP2C19 and CYP3A4 substrate]</em></p><p><em>&nbsp;</em></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Omeprazole C<sub>max</sub> &shy; 116%<br />Omeprazole AUCt &shy; 280%</p><p>Voriconazole C<sub>max</sub> &shy; 15%<br />Voriconazole AUCt &shy; 41%</p><p>&nbsp;</p><p>Other proton pump inhibitors that are CYP2C19 substrates may also be inhibited by voriconazole and may result in increased plasma concentrations of these medicinal products.</p></td><td style="vertical-align:top"><p>No dose adjustment of voriconazole is recommended.</p><p>&nbsp;</p><p>When initiating voriconazole in patients already receiving omeprazole doses of 40&nbsp;mg or above, it is recommended that the omeprazole dose be halved.</p></td></tr><tr><td style="vertical-align:top"><p>Oral Contraceptives<sup>*</sup></p><p><em>[CYP3A4 substrate; CYP2C19 inhibitor]</em></p><p>Norethisterone/ethinylestradiol (1&nbsp;mg/0.035&nbsp;mg QD)</p></td><td style="vertical-align:top"><p>Ethinylestradiol C<sub>max</sub> &shy; 36%<br />Ethinylestradiol AUCt &shy; 61%</p><p>Norethisterone C<sub>max</sub> &shy; 15%<br />Norethisterone AUCt &shy; 53%</p><p>Voriconazole C<sub>max</sub> &shy; 14%<br />Voriconazole AUCt &shy; 46%</p></td><td style="vertical-align:top"><p>Monitoring for adverse reactions related to oral contraceptives, in addition to those for voriconazole, is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Short-acting Opiates</p><p><em>[CYP3A4 substrates]</em><br />&nbsp;</p><p>Alfentanil (20&nbsp;&mu;g/kg single dose, with concomitant naloxone)<br />&nbsp;</p><p>Fentanyl (5&nbsp;g/kg single dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>In an independent published study,</p><p>Alfentanil AUC<sub>0-</sub><sub>&yen;</sub> &shy; 6-fold</p><p>&nbsp;</p><p>&nbsp;</p><p>In an independent published study,</p><p>Fentanyl AUC<sub>0-</sub><sub>&yen;</sub> &shy; 1.34-fold</p></td><td style="vertical-align:top"><p>Dose reduction of alfentanil, fentanyl and other short-acting opiates similar in structure to alfentanil and metabolised by CYP3A4 (e.g.,&nbsp;sufentanil) should be considered. Extended and frequent monitoring for respiratory depression and other opiate‑associated adverse reactions is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Statins (e.g., lovastatin)<br /><em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to increase the plasma concentrations of statins that are metabolised by CYP3A4 and could lead to rhabdomyolysis.</p></td><td style="vertical-align:top"><p>If concomitant administration of voriconazole with statins metabolised by CYP3A4 cannot be avoided, dose reduction of the statin should be considered.</p></td></tr><tr><td style="vertical-align:top"><p>Sulfonylureas (including but not limited to: tolbutamide, glipizide, glyburide)</p><p><em>[CYP2C9 substrates]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to increase the plasma concentrations of sulfonylureas and cause hypoglycaemia.</p></td><td style="vertical-align:top"><p>Careful monitoring of blood glucose is recommended. Dose reduction of sulfonylureas should be considered.</p></td></tr><tr><td style="vertical-align:top"><p>Vinca Alkaloids (including but not limited to: vincristine and vinblastine)<br /><em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to increase the plasma concentrations of vinca alkaloids and lead to neurotoxicity.</p></td><td style="vertical-align:top"><p>Dose reduction of vinca alkaloids should be considered.</p></td></tr><tr><td style="vertical-align:top"><p>Other HIV Protease Inhibitors (including but not limited to: saquinavir, amprenavir and nelfinavir)<sup>*</sup><br /><em>[CYP3A4 substrates and inhibitors]</em></p></td><td style="vertical-align:top"><p>Not studied clinically. <em>In vitro</em> studies show that voriconazole may inhibit the metabolism of HIV protease inhibitors and the metabolism of voriconazole may also be inhibited by HIV protease inhibitors.</p></td><td style="vertical-align:top"><p>Careful monitoring for any occurrence of drug toxicity and/or lack of efficacy, and dose adjustment may be needed.</p></td></tr><tr><td style="vertical-align:top"><p>Other Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) (including but not limited to: delavirdine, nevirapine)<sup>*</sup><br /><em>[CYP3A4 substrates, inhibitors or CYP450 inducers]</em></p></td><td style="vertical-align:top"><p>Not studied clinically.<em> In vitro</em> studies show that the metabolism of voriconazole may be inhibited by NNRTIs and voriconazole may inhibit the metabolism of NNRTIs.</p><p>The findings of the effect of efavirenz on voriconazole suggest that the metabolism of voriconazole may be induced by an NNRTI.</p></td><td style="vertical-align:top"><p>Careful monitoring for any occurrence of drug toxicity and/or lack of efficacy, and dose adjustment may be needed.</p></td></tr><tr><td style="vertical-align:top"><p>Tretinoin</p><p><em>[CYP3A4 substrate]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole may increase tretinoin concentrations and increase risk of adverse reactions (pseudotumor cerebri, hypercalcaemia).</p></td><td style="vertical-align:top"><p>Dose adjustment of tretinoin is recommended during treatment with voriconazole and after its discontinuation.</p></td></tr><tr><td style="vertical-align:top"><p>Cimetidine (400&nbsp;mg BID)<br /><em>[non-specific CYP450 inhibitor and increases gastric pH]</em></p></td><td style="vertical-align:top"><p>Voriconazole C<sub>max</sub> &shy; 18%<br />Voriconazole AUCt &shy; 23%</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>Digoxin (0.25&nbsp;mg QD)<br /><em>[P-gp substrate]</em></p></td><td style="vertical-align:top"><p>Digoxin C<sub>max</sub> &harr;<br />Digoxin AUCt &harr;</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>Indinavir (800&nbsp;mg TID)<br /><em>[CYP3A4 inhibitor and substrate]</em></p></td><td style="vertical-align:top"><p>Indinavir C<sub>max</sub> &harr;<br />Indinavir AUCt &harr;</p><p>Voriconazole C<sub>max</sub> &harr;<br />Voriconazole AUCt &harr;</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>Macrolide antibiotics</p><p>&nbsp;</p><p>Erythromycin (1&nbsp;g BID)<br /><em>[CYP3A4 inhibitor]</em></p><p>&nbsp;</p><p>Azithromycin (500&nbsp;mg QD)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Voriconazole C<sub>max</sub> and AUCt &harr;</p><p>&nbsp;</p><p>&nbsp;</p><p>Voriconazole C<sub>max</sub> and AUCt &harr;</p><p>&nbsp;</p><p>The effect of voriconazole on either erythromycin or azithromycin is unknown.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>No dose adjustment</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mycophenolic acid (1&nbsp;g single dose)</p><p><em>[UDP-glucuronyl transferase substrate]</em></p></td><td style="vertical-align:top"><p>Mycophenolic acid C<sub>max</sub> &harr;<br />Mycophenolic acid AUC<sub>t</sub> &harr;</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>Corticosteroids</p><p>&nbsp;</p><p>Prednisolone (60&nbsp;mg single dose)<br /><em>[CYP3A4 substrate]</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Prednisolone C<sub>max</sub> &shy; 11%<br />Prednisolone AUC<sub>0-</sub><sub>&yen;</sub> &shy; 34%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>No dose adjustment</p><p>&nbsp;</p><p>Patients on long-term treatment with voriconazole and corticosteroids (including inhaled corticosteroids e.g., budesonide and intranasal corticosteroids) should be carefully monitored for adrenal cortex dysfunction both during treatment and when voriconazole is discontinued (see section 4.4).</p></td></tr><tr><td style="vertical-align:top"><p>Ranitidine (150&nbsp;mg BID)<br /><em>[increases gastric pH]</em></p></td><td style="vertical-align:top"><p>Voriconazole C<sub>max</sub> and AUCt &harr;</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no adequate data on the use of VFEND in pregnant women available.</p><p>&nbsp;</p><p>Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.</p><p>&nbsp;</p><p>VFEND must not be used during pregnancy unless the benefit to the mother clearly outweighs the potential risk to the foetus.</p><p>&nbsp;</p><p><u>Women of child-bearing potential </u></p><p>Women of child-bearing potential must always use effective contraception during treatment.</p><p>&nbsp;</p><p><u>Breast-feeding </u></p><p>The excretion of voriconazole into breast milk has not been investigated. Breast-feeding must be stopped on initiation of treatment with VFEND.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>In an animal study, no impairment of fertility was demonstrated in male and female rats (see section 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>VFEND has moderate influence on the ability to drive and use machines. It may cause transient and reversible changes to vision, including blurring, altered/enhanced visual perception and/or photophobia. Patients must avoid potentially hazardous tasks, such as driving or operating machinery while experiencing these symptoms.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of safety profile</u></p><p>The safety profile of voriconazole in adults is based on an integrated safety database of more than 2,000&nbsp;subjects (including 1,603 adult patients in therapeutic trials) and an additional 270 adults in prophylaxis trials. This represents a heterogeneous population, containing patients with haematological malignancy, HIV-infected patients with oesophageal candidiasis and refractory fungal infections, non‑neutropenic patients with candidaemia or aspergillosis and healthy volunteers.</p><p>&nbsp;</p><p>The most commonly reported adverse reactions were visual impairment, pyrexia, rash, vomiting, nausea, diarrhoea, headache, peripheral oedema, liver function test abnormal, respiratory distress and abdominal pain.</p><p>&nbsp;</p><p>The severity of the adverse reactions was generally mild to moderate. No clinically significant differences were seen when the safety data were analysed by age, race, or gender.</p><p><u>&nbsp;</u></p><p><u>Tabulated list of adverse reactions</u></p><p>In the table below, since the majority of the studies were of an open nature, all causality adverse reactions and their frequency categories in 1,873 adults from pooled therapeutic (1,603) and prophylaxis (270) studies, by system organ class, are listed.</p><p>&nbsp;</p><p>Frequency categories are expressed as: Very common (&sup3;1/10); Common (&sup3;1/100 to &lt;1/10); Uncommon (&sup3;1/1,000 to &lt;1/100); Rare (&sup3;1/10,000 to &lt;1/1,000); Very rare (&lt;1/10,000); Not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>Undesirable effects reported in subjects receiving voriconazole:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p><p><strong>&ge; 1/10</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>&ge; 1/100</strong></p><p><strong>to &lt; 1/10</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>&ge; 1/1,000 to &lt;</strong></p><p><strong>1/100</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>&ge; 1/10,000 to &lt;</strong></p><p><strong>1/1,000</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p><p><strong>not known</strong></p><p><strong>(cannot be</strong></p><p><strong>estimated</strong></p><p><strong>from</strong></p><p><strong>available</strong></p><p><strong>data)</strong></p><p><strong>&nbsp;</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>sinusitis</p></td><td style="vertical-align:top"><p>pseudomembranous colitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (including cysts and polyps)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>squamous cell carcinoma (including cutaneous SCC in situ, or Bowen&rsquo;s disease)*,**</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>agranulocytosis<sup>1</sup>, pancytopenia, thrombocytopenia<sup>2</sup>, leukopenia, anaemia</p></td><td style="vertical-align:top"><p>bone marrow failure, lymphadenopathy, eosinophilia</p></td><td style="vertical-align:top"><p>disseminated intravascular coagulation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypersensitivity</p></td><td style="vertical-align:top"><p>anaphylactoid reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>adrenal insufficiency, hypothyroidism</p></td><td style="vertical-align:top"><p>hyperthyroidism</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>oedema peripheral</p></td><td style="vertical-align:top"><p>hypoglycaemia, hypokalaemia, hyponatraemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>depression, hallucination, anxiety, insomnia, agitation, confusional state</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>convulsion, syncope, tremor, hypertonia<sup>3</sup>, paraesthesia, somnolence, dizziness</p></td><td style="vertical-align:top"><p>brain oedema, encephalopathy<sup>4</sup>, extrapyramidal disorder<sup>5</sup>, neuropathy peripheral, ataxia, hypoaesthesia, dysgeusia</p></td><td style="vertical-align:top"><p>hepatic encephalopathy, Guillain-Barre syndrome, nystagmus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>visual impairment<sup>6</sup></p></td><td style="vertical-align:top"><p>retinal haemorrhage</p></td><td style="vertical-align:top"><p>optic nerve disorder<sup>7</sup>, papilloedema<sup>8</sup>, oculogyric crisis, diplopia, scleritis, blepharitis</p></td><td style="vertical-align:top"><p>optic atrophy, corneal opacity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypoacusis, vertigo, tinnitus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>arrhythmia supraventricular, tachycardia, bradycardia</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>ventricular fibrillation, ventricular extrasystoles, ventricular tachycardia, electrocardiogram QT prolonged, supraventricular tachycardia</p></td><td style="vertical-align:top"><p>torsades de pointes, atrioventricular block complete, bundle branch block, nodal rhythm</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypotension, phlebitis</p></td><td style="vertical-align:top"><p>thrombophlebitis, lymphangitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>respiratory distress<sup>9</sup></p></td><td style="vertical-align:top"><p>acute respiratory distress syndrome, pulmonary oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>diarrhoea, vomiting, abdominal pain, nausea</p></td><td style="vertical-align:top"><p>cheilitis, dyspepsia, constipation, gingivitis</p></td><td style="vertical-align:top"><p>peritonitis, pancreatitis, swollen tongue, duodenitis, gastroenteritis, glossitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>liver function test abnormal</p></td><td style="vertical-align:top"><p>jaundice, jaundice cholestatic, hepatitis<sup>10</sup></p></td><td style="vertical-align:top"><p>hepatic failure, hepatomegaly, cholecystitis, cholelithiasis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>rash</p></td><td style="vertical-align:top"><p>dermatitis exfoliative, alopecia, rash maculo-papular, pruritus, erythema, phototoxicity**</p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome<sup>8</sup>, purpura, urticaria, dermatitis allergic, rash papular, rash macular, eczema</p></td><td style="vertical-align:top"><p>toxic epidermal necrolysis<sup>8</sup>, drug reaction with eosinophilia and systemic symptoms (DRESS)<sup>8</sup>, angioedema, actinic keratosis*, pseudoporphyria, erythema multiforme, psoriasis, drug eruption</p></td><td style="vertical-align:top"><p>cutaneous lupus erythematosus*, ephelides*, lentigo*</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>back pain</p></td><td style="vertical-align:top"><p>arthritis, periostitis*,**</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>renal failure acute, haematuria</p></td><td style="vertical-align:top"><p>renal tubular necrosis, proteinuria, nephritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>pyrexia</p></td><td style="vertical-align:top"><p>chest pain, face oedema<sup>11</sup>, asthenia, chills</p></td><td style="vertical-align:top"><p>infusion site reaction, influenza like illness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>blood creatinine increased</p></td><td style="vertical-align:top"><p>blood urea increased, blood cholesterol increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>*ADR identified post-marketing</p><p>**Frequency category is based on an observational study utilising real-world data from secondary data sources in Sweden</p><p><sup>1 </sup>Includes febrile neutropenia and neutropenia.</p><p><sup>2</sup> Includes immune thrombocytopenic purpura.</p><p><sup>3</sup> Includes nuchal rigidity and tetany.</p><p><sup>4</sup> Includes hypoxic-ischaemic encephalopathy and metabolic encephalopathy.</p><p><sup>5</sup> Includes akathisia and parkinsonism.</p><p><sup>6</sup> See &ldquo;Visual impairments&rdquo; paragraph in section 4.8.</p><p><sup>7</sup> Prolonged optic neuritis has been reported post-marketing. See section 4.4.</p><p><sup>8</sup> See section 4.4.</p><p><sup>9</sup> Includes dyspnoea and dyspnoea exertional.</p><p><sup>10</sup> Includes drug-induced liver injury, hepatitis toxic, hepatocellular injury and hepatotoxicity.</p><p><sup>11</sup> Includes periorbital oedema, lip oedema, and oedema mouth.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Visual impairments</em></p><p>In clinical trials, visual impairments (including blurred vision, photophobia, chloropsia, chromatopsia, colour blindness, cyanopsia, eye disorder, halo vision, night blindness, oscillopsia, photopsia, scintillating scotoma, visual acuity reduced, visual brightness, visual field defect, vitreous floaters, and xanthopsia) with voriconazole were very common. These visual impairments were transient and fully reversible, with the majority spontaneously resolving within 60 minutes and no clinically significant long-term visual effects were observed. There was evidence of attenuation with repeated doses of voriconazole. The visual impairments were generally mild, rarely resulted in discontinuation and were not associated with long-term sequelae. Visual impairments may be associated with higher plasma concentrations and/or doses.</p><p>&nbsp;</p><p>The mechanism of action is unknown, although the site of action is most likely to be within the retina. In a study in healthy volunteers investigating the impact of voriconazole on retinal function, voriconazole caused a decrease in the electroretinogram (ERG) waveform amplitude. The ERG measures electrical currents in the retina. The ERG changes did not progress over 29 days of treatment and were fully reversible on withdrawal of voriconazole.</p><p>&nbsp;</p><p>There have been post-marketing reports of prolonged visual adverse events (see section 4.4).</p><p><em>&nbsp;</em></p><p><em>Dermatological reactions </em></p><p>Dermatological reactions were very common in patients treated with voriconazole in clinical trials, but these patients had serious underlying diseases and were receiving multiple concomitant medicinal products. The majority of rashes were of mild to moderate severity. Patients have developed severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) (uncommon), toxic epidermal necrolysis (TEN) (rare), drug reaction with eosinophilia and systemic symptoms (DRESS) (rare) and erythema multiforme (rare) during treatment with VFEND (see section 4.4).</p><p>&nbsp;</p><p>If a patient develops a rash they should be monitored closely and VFEND discontinued if lesions progress. Photosensitivity reactions such as ephelides, lentigo and actinic keratosis have been reported, especially during long-term therapy (see section 4.4).</p><p>&nbsp;</p><p>There have been reports of squamous cell carcinoma of the skin (including cutaneous SCC in situ, or Bowen&rsquo;s disease) in patients treated with VFEND for long periods of time; the mechanism has not been established (see section 4.4).</p><p>&nbsp;</p><p><em>Liver function tests</em></p><p>The overall incidence of transaminase increases &gt;3 xULN (not necessarily comprising an adverse event) in the voriconazole clinical programme was 18.0% (319/1,768) in adults and 25.8% (73/283) in paediatric subjects who received voriconazole for pooled therapeutic and prophylaxis use. Liver function test abnormalities may be associated with higher plasma concentrations and/or doses. The majority of abnormal liver function tests either resolved during treatment without dose adjustment or following dose adjustment, including discontinuation of therapy.</p><p>&nbsp;</p><p>Voriconazole has been associated with cases of serious hepatic toxicity in patients with other serious underlying conditions. This includes cases of jaundice, hepatitis and hepatic failure leading to death (see section 4.4).</p><p>&nbsp;</p><p><em>Infusion-related reactions </em></p><p>During infusion of the intravenous formulation of voriconazole in healthy subjects, anaphylactoid-type reactions, including flushing, fever, sweating, tachycardia, chest tightness, dyspnoea, faintness, nausea, pruritus and rash have occurred. Symptoms appeared immediately upon initiating the infusion (see section 4.4).</p><p>&nbsp;</p><p><em>Prophylaxis</em><strong> </strong></p><p>In an open-label, comparative, multicenter study comparing voriconazole and itraconazole as primary prophylaxis in adult and adolescent allogeneic HSCT recipients without prior proven or probable IFI, permanent discontinuation of voriconazole due to AEs was reported in 39.3% of subjects versus 39.6% of subjects in the itraconazole arm. Treatment-emergent hepatic AEs resulted in permanent discontinuation of study medication for 50 subjects (21.4%) treated with voriconazole and for 18 subjects (7.1%) treated with itraconazole.</p><p><em>&nbsp;</em></p><p><em>Paediatric population </em></p><p>The safety of voriconazole was investigated in 288 paediatric patients aged 2 to &lt;12 years (169) and 12 to &lt;18&nbsp;years (119) who received voriconazole for prophylaxis (183) and therapeutic use (105) in clinical trials. The safety of voriconazole was also investigated in 158 additional paediatric patients aged 2 to &lt;12&nbsp;years in compassionate use programs. Overall, the safety profile of voriconazole in paediatric population was similar to that in adults. However, a trend towards a higher frequency of liver enzyme elevations, reported as adverse events in clinical trials was observed in paediatric patients as compared to adults (14.2% transaminases increased in paediatrics compared to 5.3% in adults). Post-marketing data suggest there might be a higher occurrence of skin reactions (especially erythema) in the paediatric population compared to adults. In the 22 patients less than 2 years old who received voriconazole in a compassionate use programme, the following adverse reactions (for which a relationship to voriconazole could not be excluded) were reported: photosensitivity reaction (1), arrhythmia (1), pancreatitis (1), blood bilirubin increased (1), hepatic enzymes increased (1), rash (1) and papilloedema (1). There have been post-marketing reports of pancreatitis in paediatric patients.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions </u></p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via national reporting system.</p><p><strong>&nbsp;</strong></p><p><strong>T</strong><strong>o report any side effect(s):</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC states: </strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Please Contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical trials there were 3 cases of accidental overdose. All occurred in paediatric patients, who received up to five times the recommended intravenous dose of voriconazole. A single adverse reaction of photophobia of 10 minutes duration was reported.</p><p>&nbsp;</p><p>There is no known antidote to voriconazole.</p><p>&nbsp;</p><p>Voriconazole is haemodialysed with a clearance of 121&nbsp;ml/min. The intravenous vehicle, SBECD, is haemodialysed with a clearance of 55&nbsp;ml/min. In an overdose, haemodialysis may assist in the removal of voriconazole and SBECD from the body.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Pharmacotherapeutic group: Antimycotics for systemic use, triazole derivatives, ATC code: J02A C03</p><p>&nbsp;</p><p><u>Mode of action</u></p><p>Voriconazole is a triazole antifungal agent. The primary mode of action of voriconazole is the inhibition of fungal cytochrome P450-mediated 14 alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis. The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell membrane and may be responsible for the antifungal activity of voriconazole. Voriconazole has been shown to be more selective for fungal cytochrome P-450 enzymes than for various mammalian cytochrome P-450 enzyme systems.</p><p>&nbsp;</p><p><u>Pharmacokinetic/pharmacodynamic relationship</u></p><p>In 10 therapeutic studies, the median for the average and maximum plasma concentrations in individual subjects across the studies was 2425 ng/ml (inter-quartile range 1193 to 4380 ng/ml) and 3742&nbsp;ng/ml (inter‑quartile range 2027 to 6302 ng/ml), respectively. A positive association between mean, maximum or minimum plasma voriconazole concentration and efficacy in therapeutic studies was not found and this relationship has not been explored in prophylaxis studies.</p><p>&nbsp;</p><p>Pharmacokinetic-Pharmacodynamic analyses of clinical trial data identified positive associations between plasma voriconazole concentrations and both liver function test abnormalities and visual disturbances. Dose adjustments in prophylaxis studies have not been explored.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety </u></p><p><em>In vitro</em>, voriconazole displays broad-spectrum antifungal activity with antifungal potency against <em>Candida </em>species (including fluconazole -resistant <em>C. krusei </em>and resistant strains of <em>C. glabrata</em> and <em>C. albicans</em>) and fungicidal activity against all <em>Aspergillus </em>species tested. In addition voriconazole shows <em>in vitro</em> fungicidal activity against emerging fungal pathogens, including those such as <em>Scedosporium</em> or <em>Fusarium</em> which have limited susceptibility to existing antifungal agents.</p><p>&nbsp;</p><p>Clinical efficacy defined as partial or complete response, has been demonstrated for <em>Aspergillus</em> spp. including <em>A. flavus, A. fumigatus, A. terreus, A. niger, A. nidulans; Candida </em>spp.<em>, </em>including<em> C. albicans, C. glabrata, C. krusei, C. parapsilosis and C. tropicalis; </em>and limited numbers of<em> C. dubliniensis, C. inconspicua, </em>and<em> C. guilliermondii, Scedosporium</em> spp., including<em> S. apiospermum, S. prolificans; </em>and<em> Fusarium</em> spp.</p><p>&nbsp;</p><p>Other treated fungal infections (often with either partial or complete response) included isolated cases of <em>Alternaria </em>spp., <em>Blastomyces dermatitidis, Blastoschizomyces capitatus, Cladosporium </em>spp<em>., Coccidioides immitis, Conidiobolus coronatus, Cryptococcus neoformans, Exserohilum rostratum, Exophiala spinifera, Fonsecaea pedrosoi, Madurella mycetomatis, Paecilomyces lilacinus, Penicillium spp. including P. marneffei, Phialophora richardsiae, Scopulariopsis brevicaulis and Trichosporon </em>spp. including<em> T. beigelii </em>infections.</p><p>&nbsp;</p><p><em>In vitro</em> activity against clinical isolates has been observed for <em>Acremonium </em>spp., <em>Alternaria </em>spp., <em>Bipolaris </em>spp<em>., Cladophialophora</em> spp.<em>, </em>and<em> Histoplasma capsulatum, </em>with most strains being inhibited by concentrations of voriconazole in the range 0.05 to 2&nbsp;&micro;g/ml.</p><p>&nbsp;</p><p><em>In vitro </em>activity against the following pathogens has been shown, but the clinical significance is unknown: <em>Curvularia</em> spp. and<em> Sporothrix</em> spp.</p><p>&nbsp;</p><p><u>Breakpoints</u></p><p>Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.</p><p>&nbsp;</p><p>The species most frequently involved in causing human infections include <em>C. albicans, C. parapsilosis, C. tropicalis, C. glabrata </em>and<em> C. krusei</em>, all of which usually exhibit minimal inhibitory concentration (MICs) of less than 1&nbsp;mg/L for voriconazole.</p><p>&nbsp;</p><p>However, the<em> in vitro</em> activity of voriconazole against <em>Candida </em>species is not uniform. Specifically, for <em>C. glabrata, </em>the MICs of voriconazole for fluconazole-resistant isolates are proportionally higher than are those of fluconazole-susceptible isolates. Therefore, every attempt should be made to identify <em>Candida</em> to species level. If antifungal susceptibility testing is available, the MIC results may be interpreted using breakpoint criteria established by European Committee on Antimicrobial Susceptibility Testing (EUCAST).</p><p>&nbsp;</p><p><u>EUCAST Breakpoints</u></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Candida and Aspergillus species</p></td><td colspan="2" style="vertical-align:top"><p>Minimal Inhibitory Concentration (MIC) breakpoint (mg/L)</p></td></tr><tr><td style="vertical-align:top"><p>&le;S (Susceptible)</p></td><td style="vertical-align:top"><p>&gt;R (Resistant)</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida albicans<sup>1</sup></em></p></td><td style="vertical-align:top"><p>0.06</p></td><td style="vertical-align:top"><p>0.25</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida dubliniensis<sup>1</sup></em></p></td><td style="vertical-align:top"><p>0.06</p></td><td style="vertical-align:top"><p>0.25</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida glabrata</em></p></td><td style="vertical-align:top"><p>Insufficient evidence (IE)</p></td><td style="vertical-align:top"><p>IE</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida krusei</em></p></td><td style="vertical-align:top"><p>IE</p></td><td style="vertical-align:top"><p>IE</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida parapsilosis<sup>1</sup></em></p></td><td style="vertical-align:top"><p>0.125</p></td><td style="vertical-align:top"><p>0.25</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida tropicalis<sup>1</sup></em></p></td><td style="vertical-align:top"><p>0.125</p></td><td style="vertical-align:top"><p>0.25</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida guilliermondii<sup>2</sup></em></p></td><td style="vertical-align:top"><p>IE</p></td><td style="vertical-align:top"><p>IE</p></td></tr><tr><td style="vertical-align:top"><p>Non-species related breakpoints for<em> Candida<sup>3</sup></em></p></td><td style="vertical-align:top"><p>IE</p></td><td style="vertical-align:top"><p>IE</p></td></tr><tr><td style="vertical-align:top"><p><em>Aspergillus fumigatus<sup>4</sup></em></p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><em>Aspergillus nidulans<sup>4</sup></em></p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><em>Aspergillus flavus<strong> </strong></em></p></td><td style="vertical-align:top"><p>IE<sup>5</sup></p></td><td style="vertical-align:top"><p>IE<sup>5</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Aspergillus niger</em></p></td><td style="vertical-align:top"><p>IE<sup>5</sup></p></td><td style="vertical-align:top"><p>IE<sup>5</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Aspergillus terreus</em></p></td><td style="vertical-align:top"><p>IE<sup>5</sup></p></td><td style="vertical-align:top"><p>IE<sup>5</sup></p></td></tr><tr><td style="vertical-align:top"><p>Non-species related breakpoints<sup>6</sup></p></td><td style="vertical-align:top"><p>IE</p></td><td style="vertical-align:top"><p>IE</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>1</sup> Strains with MIC values above the Susceptible/Intermediate (S/I) breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A&nbsp;clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of <em>C. albicans, C. dubliniensis, C. parapsilosis </em>and <em>C. tropicalis</em> are considered susceptible.</p><p><sup>2</sup> The epidemiological cut-off values (ECOFFs) for these species are in general higher than for <em>C. albicans</em>.</p><p><sup>3</sup> Non-species related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific <em>Candida </em>species. They are for use only for organisms that do not have specific breakpoints.</p><p><sup>4</sup> Area of technical uncertainty (ATU) is 2. Report as R with the following comment: &quot;In some clinical situations (non-invasive infections forms) voriconazole can be used provided sufficient exposure is ensured&quot;.</p><p><sup>5</sup> The ECOFFs for these species are in general one two-fold dilution higher than for <em>A. fumigatus</em>.</p><p><sup>6 </sup>Non-species related breakpoints have not been determined.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Clinical experience </u></p><p>Successful outcome in this section is defined as complete or partial response.</p><p>&nbsp;</p><p><em><u>Aspergillus</u></em><u> infections &ndash; efficacy in aspergillosis patients with poor prognosis </u></p><p>Voriconazole has <em>in vitro </em>fungicidal activity against <em>Aspergillus </em>spp. The efficacy and survival benefit of voriconazole versus conventional amphotericin B in the primary treatment of acute invasive aspergillosis was demonstrated in an open, randomised, multicentre study in 277 immunocompromised patients treated for 12 weeks. Voriconazole was administered intravenously with a loading dose of 6 mg/kg every 12&nbsp;hours for the first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours for a minimum of 7&nbsp;days. Therapy could then be switched to the oral formulation at a dose of 200 mg every 12 hours. Median duration of IV voriconazole therapy was 10 days (range 2-85 days). After IV voriconazole therapy, the median duration of oral voriconazole therapy was 76 days (range 2-232 days).</p><p>&nbsp;</p><p>A satisfactory global response (complete or partial resolution of all attributable symptoms, signs, radiographic/bronchoscopic abnormalities present at baseline) was seen in 53% of voriconazole-treated patients compared to 31% of patients treated with comparator. The 84-day survival rate for voriconazole was statistically significantly higher than that for the comparator and a clinically and statistically significant benefit was shown in favour of voriconazole for both time to death and time to discontinuation due to toxicity.</p><p>&nbsp;</p><p>This study confirmed findings from an earlier, prospectively designed study where there was a positive outcome in subjects with risk factors for a poor prognosis, including graft versus host disease, and, in particular, cerebral infections (normally associated with almost 100% mortality).</p><p>&nbsp;</p><p>The studies included cerebral, sinus, pulmonary and disseminated aspergillosis in patients with bone marrow and solid organ transplants, haematological malignancies, cancer and AIDS.</p><p>&nbsp;</p><p><u>Candidaemia in non-neutropenic patients</u></p><p>The efficacy of voriconazole compared to the regimen of amphotericin B followed by fluconazole in the primary treatment of candidaemia was demonstrated in an open, comparative study. Three hundred and seventy non-neutropenic patients (above 12 years of age) with documented candidaemia were included in the study, of whom 248 were treated with voriconazole. Nine subjects in the voriconazole group and 5 in the amphotericin B followed by fluconazole group also had mycologically proven infection in deep tissue. Patients with renal failure were excluded from this study. The median treatment duration was 15&nbsp;days in both treatment arms. In the primary analysis, successful response as assessed by a Data Review Committee (DRC) blinded to study medicinal product was defined as resolution/improvement in all clinical signs and symptoms of infection with eradication of <em>Candida </em>from blood and infected deep tissue sites 12&nbsp;weeks after the end of therapy (EOT). Patients who did not have an assessment 12 weeks after EOT were counted as failures. In this analysis a successful response was seen in 41% of patients in both treatment arms.</p><p>&nbsp;</p><p>In a secondary analysis, which utilised DRC<em> </em>assessments at the latest evaluable time point (EOT, or 2, 6, or 12&nbsp;weeks after EOT) voriconazole and the regimen of amphotericin B followed by fluconazole had successful response rates of 65% and 71%, respectively.</p><p>&nbsp;</p><p>The Investigator&rsquo;s assessment of successful outcome at each of these time points is shown in the following table.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong><em>Timepoint </em></strong></p></td><td style="vertical-align:top"><p><strong><em>Voriconazole </em></strong></p><p>(N=248)</p></td><td style="vertical-align:top"><p><strong><em>Amphotericin B &rarr; fluconazole </em></strong></p><p>(N=122)</p></td></tr><tr><td><p>EOT</p></td><td><p>178 (72%)</p></td><td><p>88 (72%)</p></td></tr><tr><td style="vertical-align:top"><p>2 weeks after EOT</p></td><td style="vertical-align:top"><p>125 (50%)</p></td><td style="vertical-align:top"><p>62 (51%)</p></td></tr><tr><td style="vertical-align:top"><p>6 weeks after EOT</p></td><td style="vertical-align:top"><p>104 (42%)</p></td><td style="vertical-align:top"><p>55 (45%)</p></td></tr><tr><td style="vertical-align:top"><p>12 weeks after EOT</p></td><td style="vertical-align:top"><p>104 (42%)</p></td><td style="vertical-align:top"><p>51 (42%)</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Serious refractory <em>Candida</em> infections </u></p><p>The study comprised 55 patients with serious refractory systemic <em>Candida</em> infections (including candidaemia, disseminated and other invasive candidiasis) where prior antifungal treatment, particularly with fluconazole, had been ineffective. Successful response was seen in 24 patients (15 complete, 9 partial responses). In fluconazole-resistant non-<em>albicans</em> species, a successful outcome was seen in 3/3 <em>C. krusei</em> (complete responses) and 6/8 <em>C. glabrata</em> (5 complete, 1 partial response) infections. The clinical efficacy data were supported by limited susceptibility data.</p><p>&nbsp;</p><p><em><u>Scedosporium</u></em><u> and <em>Fusarium</em> infections </u></p><p>Voriconazole was shown to be effective against the following rare fungal pathogens:</p><p>&nbsp;</p><p><em>Scedosporium</em> spp.: Successful response to voriconazole therapy was seen in 16 (6 complete, 10 partial responses) of 28 patients with <em>S. apiospermum </em>and in 2 (both partial responses) of 7 patients with <em>S. prolificans </em>infection. In addition, a successful response was seen in 1 of 3 patients with infections caused by more than one organism including <em>Scedosporium</em> spp.</p><p>&nbsp;</p><p><em>Fusarium</em> spp.: Seven (3 complete, 4 partial responses) of 17 patients were successfully treated with voriconazole. Of these 7 patients, 3 had eye, 1 had sinus, and 3 had disseminated infection. Four additional patients with fusariosis had an infection caused by several organisms; 2 of them had a successful outcome.</p><p>&nbsp;</p><p>The majority of patients receiving voriconazole treatment of the above mentioned rare infections were intolerant of, or refractory to, prior antifungal therapy.</p><p>&nbsp;</p><p><u>Primary Prophylaxis of Invasive Fungal Infections &ndash; Efficacy in HSCT recipients without prior proven or probable IFI</u></p><p>Voriconazole was compared to itraconazole as primary prophylaxis in an open-label, comparative, multicenter study of adult and adolescent allogeneic HSCT recipients without prior proven or probable IFI. Success was defined as the ability to continue study drug prophylaxis for 100 days after HSCT (without stopping for &gt;14 days) and survival with no proven or probable IFI for 180 days after HSCT. The modified intent-to-treat (MITT) group included 465 allogeneic HSCT recipients with 45% of patients having AML. From all patients 58% were subject to myeloablative conditions regimens. Prophylaxis with study drug was started immediately after HSCT: 224 received voriconazole and 241 received itraconazole. The median duration of study drug prophylaxis was 96 days for voriconazole and 68 days for itraconazole in the MITT group.</p><p>&nbsp;</p><p>Success rates and other secondary endpoints are presented in the table below:</p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Study Endpoints</strong></p></td><td style="vertical-align:top"><p><strong>Voriconazole<br />N=224</strong></p></td><td style="vertical-align:top"><p><strong>Itraconazole<br />N=241</strong></p></td><td style="vertical-align:top"><p><strong>Difference in proportions and the 95% confidence interval (CI) </strong></p></td><td style="vertical-align:top"><p><strong>P-Value</strong></p></td></tr><tr><td style="vertical-align:top"><p>Success at day 180*</p></td><td style="vertical-align:top"><p>109 (48.7%)</p></td><td style="vertical-align:top"><p>80 (33.2%)</p></td><td style="vertical-align:top"><p>16.4% (7.7%, 25.1%)**</p></td><td style="vertical-align:top"><p>0.0002**</p></td></tr><tr><td style="vertical-align:top"><p>Success at day 100</p></td><td style="vertical-align:top"><p>121 (54.0%)</p></td><td style="vertical-align:top"><p>96 (39.8%)</p></td><td style="vertical-align:top"><p>15.4% (6.6%, 24.2%)**</p></td><td style="vertical-align:top"><p>0.0006**</p></td></tr><tr><td style="vertical-align:top"><p>Completed at least 100 days of study drug prophylaxis</p></td><td style="vertical-align:top"><p>120 (53.6%)</p></td><td style="vertical-align:top"><p>94 (39.0%)</p></td><td style="vertical-align:top"><p>14.6% (5.6%, 23.5%)</p></td><td style="vertical-align:top"><p>0.0015</p></td></tr><tr><td style="vertical-align:top"><p>Survived to day 180</p></td><td style="vertical-align:top"><p>184 (82.1%)</p></td><td style="vertical-align:top"><p>197 (81.7%)</p></td><td style="vertical-align:top"><p>0.4% (-6.6%, 7.4%)</p></td><td style="vertical-align:top"><p>0.9107</p></td></tr><tr><td style="vertical-align:top"><p>Developed proven or probable IFI to day 180</p></td><td style="vertical-align:top"><p>3 (1.3%)</p></td><td style="vertical-align:top"><p>5 (2.1%)</p></td><td style="vertical-align:top"><p>-0.7% (-3.1%, 1.6%)</p></td><td style="vertical-align:top"><p>0.5390</p></td></tr><tr><td style="vertical-align:top"><p>Developed proven or probable IFI to day 100</p></td><td style="vertical-align:top"><p>2 (0.9%)</p></td><td style="vertical-align:top"><p>4 (1.7%)</p></td><td style="vertical-align:top"><p>-0.8% (-2.8%, 1.3%)</p></td><td style="vertical-align:top"><p>0.4589</p></td></tr><tr><td style="vertical-align:top"><p>Developed proven or probable IFI while on study drug</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>3 (1.2%)</p></td><td style="vertical-align:top"><p>-1.2% (-2.6%, 0.2%)</p></td><td style="vertical-align:top"><p>0.0813</p></td></tr></tbody></table><p>* Primary endpoint of the study</p><p>** Difference in proportions, 95% CI and p-values obtained after adjustment for randomization</p><p>&nbsp;</p><p>The breakthrough IFI rate to Day 180 and the primary endpoint of the study, which is Success at Day&nbsp;180, for patients with AML and myeloablative conditioning regimens respectively, is presented in the table below:</p><p>&nbsp;</p><p><strong>AML</strong></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Study endpoints</strong></p></td><td style="vertical-align:top"><p><strong>Voriconazole </strong></p><p><strong>(N=98) </strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Itraconazole</strong></p><p><strong>(N=109)</strong></p></td><td style="vertical-align:top"><p><strong>Difference in proportions and the 95% confidence interval (CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Breakthrough IFI &ndash; Day 180</p></td><td style="vertical-align:top"><p>1 (1.0%)</p></td><td style="vertical-align:top"><p>&nbsp;2 (1.8%)</p></td><td style="vertical-align:top"><p>-0.8% (-4.0%, 2.4%) **</p></td></tr><tr><td style="vertical-align:top"><p>Success at Day 180*</p></td><td style="vertical-align:top"><p>55 (56.1%)</p></td><td style="vertical-align:top"><p>45 (41.3%)</p></td><td style="vertical-align:top"><p>14.7% (1.7%, 27.7%)***</p></td></tr></tbody></table><p>*&nbsp;&nbsp; Primary endpoint of study</p><p>** Using a margin of 5%, non inferiority is demonstrated</p><p>***Difference in proportions, 95% CI obtained after adjustment for randomization</p><p>&nbsp;</p><p><strong>Myeloablative conditioning regimens</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Study endpoints</strong></p></td><td style="vertical-align:top"><p><strong>Voriconazole </strong></p><p><strong>(N=125) </strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Itraconazole</strong></p><p><strong>(N=143)</strong></p></td><td style="vertical-align:top"><p><strong>Difference in proportions and the 95% confidence interval (CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Breakthrough IFI &ndash; Day 180</p></td><td style="vertical-align:top"><p>2 (1.6%)</p></td><td style="vertical-align:top"><p>3 (2.1%)</p></td><td style="vertical-align:top"><p>-0.5% (-3.7%, 2.7%) **</p></td></tr><tr><td style="vertical-align:top"><p>Success at Day 180*</p></td><td style="vertical-align:top"><p>70 (56.0%)</p></td><td style="vertical-align:top"><p>53 (37.1%)</p></td><td style="vertical-align:top"><p>20.1% (8.5%, 31.7%)***</p></td></tr></tbody></table><p>*&nbsp;&nbsp; Primary endpoint of study</p><p>** Using a margin of 5%, non inferiority is demonstrated</p><p>*** Difference in proportions, 95% CI obtained after adjustment for randomization</p><p>&nbsp;</p><p><u>Secondary Prophylaxis of IFI &ndash; Efficacy in HSCT recipients</u><u> </u><u>with prior proven or probable IFI</u></p><p>Voriconazole was investigated as secondary prophylaxis in an open-label, non-comparative, multicenter study of adult allogeneic HSCT recipients with prior proven or probable IFI. The primary endpoint was the rate of occurrence of proven and probable IFI during the first year after HSCT. The MITT group included 40&nbsp;patients with prior IFI, including 31 with aspergillosis, 5 with candidiasis, and 4 with other IFI. The median duration of study drug prophylaxis was 95.5 days in the MITT group.</p><p>&nbsp;</p><p>Proven or probable IFIs developed in 7.5% (3/40) of patients during the first year after HSCT, including one candidemia, one scedosporiosis (both relapses of prior IFI), and one zygomycosis. The survival rate at Day&nbsp;180 was 80.0% (32/40) and at 1 year was 70.0% (28/40).</p><p>&nbsp;</p><p><u>Duration of treatment </u></p><p>In clinical trials, 705 patients received voriconazole therapy for greater than 12 weeks, with 164&nbsp;patients receiving voriconazole for over 6 months.</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>Fifty-three paediatric patients aged 2 to &lt;18 years were treated with voriconazole in two prospective, open‑label, non-comparative, multi-center clinical trials. One study enrolled 31 patients with possible, proven or probable invasive aspergillosis (IA), of whom 14 patients had proven or probable IA and were included in the MITT efficacy analyses. The second study enrolled 22 patients with invasive candidiasis including candidaemia (ICC), and esophageal candidiasis (EC) requiring either primary or salvage therapy, of whom 17 were included in the MITT efficacy analyses.&nbsp;For patients with IA the overall rates of global response at 6&nbsp;weeks were 64.3% (9/14), the global response rate was 40% (2/5) for patients 2 to &lt;12 years and 77.8% (7/9) for patients 12 to &lt;18 years of age. For patients with ICC the global response rate at EOT was 85.7% (6/7) and for patients with EC the global response rate at EOT was 70% (7/10). The overall rate of response (ICC and EC combined) was 88.9% (8/9) for 2 to &lt;12 years old and 62.5% (5/8) for 12 to &lt;18&nbsp;years old.</p><p>&nbsp;</p><p><u>Clinical studies examining QTc interval </u></p><p>A placebo-controlled, randomized, single-dose, crossover study to evaluate the effect on the QTc interval of healthy volunteers was conducted with three oral doses of voriconazole and ketoconazole. The placebo‑adjusted mean maximum increases in QTc from baseline after 800, 1200 and 1600&nbsp;mg of voriconazole were 5.1, 4.8, and 8.2&nbsp;msec, respectively and 7.0&nbsp;msec for ketoconazole 800&nbsp;mg. No subject in any group had an increase in QTc of &ge; 60 msec from baseline. No subject experienced an interval exceeding the potentially clinically-relevant threshold of 500&nbsp;msec.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p><u>General pharmacokinetic characteristics </u></p><p>The pharmacokinetics of voriconazole have been characterised in healthy subjects, special populations and patients. During oral administration of 200&nbsp;mg or 300&nbsp;mg twice daily for 14 days in patients at risk of aspergillosis (mainly patients with malignant neoplasms of lymphatic or haematopoietic tissue), the observed pharmacokinetic characteristics of rapid and consistent absorption, accumulation and non-linear pharmacokinetics were in agreement with those observed in healthy subjects.</p><p>&nbsp;</p><p>The pharmacokinetics of voriconazole are non-linear due to saturation of its metabolism. Greater than proportional increase in exposure is observed with increasing dose. It is estimated that, on average, increasing the oral dose from 200&nbsp;mg twice daily to 300&nbsp;mg twice daily leads to a 2.5-fold increase in exposure (AUC&tau;). The oral maintenance dose of 200&nbsp;mg (or 100 mg for patients less than 40&nbsp;kg) achieves a voriconazole exposure similar to 3&nbsp;mg/kg IV. A 300&nbsp;mg (or 150 mg for patients less than 40&nbsp;kg) oral maintenance dose achieves an exposure similar to 4&nbsp;mg/kg IV. When the recommended intravenous or oral loading dose regimens are administered, plasma concentrations close to steady state are achieved within the first 24&nbsp;hours of dosing. Without the loading dose, accumulation occurs during twice daily multiple dosing with steady-state plasma voriconazole concentrations being achieved by Day 6 in the majority of subjects.</p><p>&nbsp;</p><p><u>Absorption </u></p><p>Voriconazole is rapidly and almost completely absorbed following oral administration, with maximum plasma concentrations (C<sub>max</sub>) achieved 1-2 hours after dosing. The absolute bioavailability of voriconazole after oral administration is estimated to be 96%. When multiple doses of voriconazole are administered with high fat meals, C<sub>max</sub> and AUC&tau; are reduced by 34% and 24%, respectively. The absorption of voriconazole is not affected by changes in gastric pH.</p><p>&nbsp;</p><p><u>Distribution </u></p><p>The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues. Plasma protein binding is estimated to be 58%.</p><p>&nbsp;</p><p>Cerebrospinal fluid samples from eight patients in a compassionate programme showed detectable voriconazole concentrations in all patients.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p><em>In vitro</em> studies showed that voriconazole is metabolised by the hepatic cytochrome P450 isoenzymes CYP2C19, CYP2C9 and CYP3A4.</p><p>&nbsp;</p><p>The inter-individual variability of voriconazole pharmacokinetics is high.</p><p>&nbsp;</p><p><em>In vivo</em> studies indicated that CYP2C19 is significantly involved in the metabolism of voriconazole. This enzyme exhibits genetic polymorphism. For example, 15-20% of Asian populations may be expected to be poor metabolisers. For Caucasians and Blacks the prevalence of poor metabolisers is 3-5%. Studies conducted in Caucasian and Japanese healthy subjects have shown that poor metabolisers have, on average, 4-fold higher voriconazole exposure (AUC&tau;) than their homozygous extensive metaboliser counterparts. Subjects who are heterozygous extensive metabolisers have on average 2-fold higher voriconazole exposure than their homozygous extensive metaboliser counterparts.</p><p>&nbsp;</p><p>The major metabolite of voriconazole is the N-oxide, which accounts for 72% of the circulating radiolabelled metabolites in plasma. This metabolite has minimal antifungal activity and does not contribute to the overall efficacy of voriconazole.</p><p>&nbsp;</p><p><u>Elimination </u></p><p>Voriconazole is eliminated via hepatic metabolism with less than 2% of the dose excreted unchanged in the urine.</p><p>&nbsp;</p><p>After administration of a radiolabelled dose of voriconazole, approximately 80% of the radioactivity is recovered in the urine after multiple intravenous dosing and 83% in the urine after multiple oral dosing. The majority (&gt;94%) of the total radioactivity is excreted in the first 96 hours after both oral and intravenous dosing.</p><p>&nbsp;</p><p>The terminal half-life of voriconazole depends on dose and is approximately 6 hours at 200&nbsp;mg (orally). Because of non-linear pharmacokinetics, the terminal half-life is not useful in the prediction of the accumulation or elimination of voriconazole.</p><p>&nbsp;</p><p><u>Pharmacokinetics in special patient groups </u></p><p><em>&nbsp;</em></p><p><em>Gender </em></p><p>In an oral multiple-dose study, C<sub>max</sub> and AUC&tau; for healthy young females were 83% and 113% higher, respectively, than in healthy young males (18-45 years)<em>. </em>In the same study, no significant differences in C<sub>max</sub> and AUC&tau; were observed between healthy elderly males and healthy elderly females (&ge;65 years).</p><p>&nbsp;</p><p>In the clinical programme, no dosage adjustment was made on the basis of gender. The safety profile and plasma concentrations observed in male and female patients were similar. Therefore, no dosage adjustment based on gender is necessary.</p><p>&nbsp;</p><p><em>Elderly </em></p><p>In an oral multiple-dose study C<sub>max</sub> and AUC&tau; in healthy elderly males (&ge;65 years) were 61% and 86% higher, respectively, than in healthy young males (18-45 years). No significant differences in C<sub>max</sub> and AUC&tau; were observed between healthy elderly females (&ge;65 years) and healthy young females (18-45 years).</p><p>&nbsp;</p><p>In the therapeutic studies no dosage adjustment was made on the basis of age. A relationship between plasma concentrations and age was observed. The safety profile of voriconazole in young and elderly patients was similar and, therefore, no dosage adjustment is necessary for the elderly (see section 4.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The recommended doses in children and adolescent patients are based on a population pharmacokinetic analysis of data obtained from 112 immunocompromised paediatric patients aged 2 to &lt;12 years and 26 immunocompromised adolescent patients aged 12 to &lt;17 years. Multiple intravenous doses of 3, 4, 6, 7 and 8&nbsp;mg/kg twice daily and multiple oral doses (using the powder for oral suspension) of 4&nbsp;mg/kg, 6&nbsp;mg/kg, and 200&nbsp;mg twice daily were evaluated in 3 paediatric pharmacokinetic studies. Intravenous loading doses of 6&nbsp;mg/kg IV twice daily on day 1 followed by 4&nbsp;mg/kg intravenous dose twice daily and 300&nbsp;mg oral tablets twice daily were evaluated in one adolescent pharmacokinetic study. Larger inter-subject variability was observed in paediatric patients compared to adults.</p><p>&nbsp;</p><p>A comparison of the paediatric and adult population pharmacokinetic data indicated that the predicted total exposure (AUC<sub>t</sub>) in children following administration of a 9&nbsp;mg/kg IV loading dose was comparable to that in adults following a 6&nbsp;mg/kg IV loading dose. The predicted total exposures in children following IV maintenance doses of 4 and 8&nbsp;mg/kg twice daily were comparable to those in adults following 3 and 4&nbsp;mg/kg IV twice daily, respectively. The predicted total exposure in children following an oral maintenance dose of 9&nbsp;mg/kg (maximum of 350&nbsp;mg) twice daily was comparable to that in adults following 200&nbsp;mg oral twice daily. An 8&nbsp;mg/kg intravenous dose will provide voriconazole exposure approximately</p><p>2-fold higher than a 9&nbsp;mg/kg oral dose.</p><p>&nbsp;</p><p>The higher intravenous maintenance dose in paediatric patients relative to adults reflects the higher elimination capacity in paediatric patients due to a greater liver mass to body mass ratio. Oral bioavailability may, however, be limited in paediatric patients with malabsorption and very low body weight for their age. In that case, intravenous voriconazole administration is recommended.</p><p>&nbsp;</p><p>Voriconazole exposures in the majority of adolescent patients were comparable to those in adults receiving the same dosing regimens. However, lower voriconazole exposure was observed in some young adolescents with low body weight compared to adults. It is likely that these subjects may metabolise voriconazole more similarly to children than to adolescents/adults. Based on the population pharmacokinetic analysis, 12- to 14‑year-old adolescents weighing less than 50&nbsp;kg should receive children&rsquo;s doses (see section 4.2).</p><p>&nbsp;</p><p><em>Renal impairment </em></p><p>In patients with moderate to severe renal dysfunction (serum creatinine levels &gt; 2.5&nbsp;mg/dl), accumulation of the intravenous vehicle, SBECD, occurs (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p><em>Hepatic impairment </em></p><p>After an oral single-dose (200&nbsp;mg), AUC was 233% higher in subjects with mild to moderate hepatic cirrhosis (Child-Pugh A and B) compared with subjects with normal hepatic function. Protein binding of voriconazole was not affected by impaired hepatic function.</p><p>&nbsp;</p><p>In an oral multiple-dose study, AUC&tau; was similar in subjects with moderate hepatic cirrhosis (Child-Pugh&nbsp;B) given a maintenance dose of 100 mg twice daily and subjects with normal hepatic function given 200&nbsp;mg twice daily. No pharmacokinetic data are available for patients with severe hepatic cirrhosis (Child-Pugh&nbsp;C) (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Repeated-dose toxicity studies with voriconazole indicated the liver to be the target organ. Hepatotoxicity occurred at plasma exposures similar to those obtained at therapeutic doses in humans, in common with other antifungal agents. In rats, mice and dogs, voriconazole also induced minimal adrenal changes. Conventional studies of safety pharmacology, genotoxicity or carcinogenic potential did not reveal a special hazard for humans.</p><p>&nbsp;</p><p>In reproduction studies, voriconazole was shown to be teratogenic in rats and embryotoxic in rabbits at systemic exposures equal to those obtained in humans with therapeutic doses. In the pre- and post-natal development study in rats at exposures lower than those obtained in humans with therapeutic doses, voriconazole prolonged the duration of gestation and labour and produced dystocia with consequent maternal mortality and reduced perinatal survival of pups. The effects on parturition are probably mediated by species-specific mechanisms, involving reduction of oestradiol levels, and are consistent with those observed with other azole antifungal agents. Voriconazole administration induced no impairment of male or female fertility in rats at exposures similar to those obtained in humans at therapeutic doses.</p><p>&nbsp;</p><p>Preclinical data on the intravenous vehicle SBECD indicated that the main effects were vacuolation of urinary tract epithelium and activation of macrophages in the liver and lungs in the repeated-dose toxicity studies. As GPMT (guinea pig maximisation test) result was positive, prescribers should be aware of the hypersensitivity potential of the intravenous formulation. Standard genotoxicity and reproduction studies with the excipient SBECD reveal no special hazard for humans. Carcinogenicity studies were not performed with SBECD. An impurity present in SBECD has been shown to be an alkylating mutagenic agent with evidence for carcinogenicity in rodents. This impurity should be considered a substance with carcinogenic potential in humans. In light of these data the duration of treatment with the intravenous formulation should be no longer than 6 months.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sulphobutylether beta cyclodextrin sodium (SBECD)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>VFEND must not be infused into the same line or cannula concomitantly with other intravenous products. The bag should be checked to ensure that the infusion is complete. When the VFEND infusion is complete, the line may be used for administration of other intravenous products<strong>. </strong></p><p>&nbsp;</p><p><u>Blood products and short-term infusion of concentrated solutions of electrolytes</u>: Electrolyte disturbances such as hypokalaemia, hypomagnesaemia and hypocalcaemia should be corrected prior to initiation of voriconazole therapy (see sections 4.2 and 4.4). VFEND must not be administered simultaneously with any blood product or any short-term infusion of concentrated solutions of electrolytes, even if the two infusions are running in separate lines.</p><p>&nbsp;</p><p><u>Total parenteral nutrition: </u>Total parenteral nutrition (TPN) need <em>not</em> be discontinued when prescribed with VFEND, but does need to be infused through a separate line. If infused through a multiple-lumen catheter, TPN needs to be administered using a different port from the one used for VFEND. VFEND must not be diluted with 4.2% Sodium Bicarbonate Infusion. Compatibility with other concentrations is unknown.</p><p>&nbsp;</p><p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months

Do not use Vfend IV after the expiry date which is stated on the carton after EXP:. The expiry date refers to the last day of that month.
 
From a microbiological point of view, once reconstituted, the product must be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C (in a refrigerator), unless reconstitution has taken place in controlled and validated aseptic conditions. 

Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C to 8°C. 

Solvent for solution for infusion: 
VFEND solvent for solution for infusion is a sterile, single use polypropylene infusion bag. Therefore, from a microbiological point of view, once solvent has been removed from the bag to reconstitute the VFEND powder for solution for infusion and then reintroduced into the bag, the product must be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless reconstitution has taken place in controlled and validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vial should be stored below 30&deg;C.</p><p>&nbsp;</p><p>For storage conditions after reconstitution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>30 ml clear Type I glass vial with rubber stopper and aluminium cap with plastic seal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.</p><p>&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p><p>&nbsp;</p><p>The powder is reconstituted with either 19&nbsp;ml of water for injections or 19&nbsp;ml of 9&nbsp;mg/ml (0.9%) Sodium Chloride for Infusion to obtain an extractable volume of 20&nbsp;ml of clear concentrate containing 10&nbsp;mg/ml of voriconazole. Discard the VFEND vial if vacuum does not pull the diluent into the vial. It is recommended that a standard 20&nbsp;ml (non-automated) syringe be used to ensure that the exact amount (19.0&nbsp;ml) of water for injections or (9&nbsp;mg/ml [0.9%]) Sodium Chloride for Infusion is dispensed. This medicinal product is for single use only and any unused solution should be discarded. Only clear solutions without particles should be used.</p><p>&nbsp;</p><p>For administration, the required volume of the reconstituted concentrate is added to a recommended compatible infusion solution (detailed in the table below) to obtain a final voriconazole solution containing 0.5-5&nbsp;mg/ml.</p><p>&nbsp;</p><p>The reconstituted solution can be diluted with:</p><p>&nbsp;</p><p>Sodium Chloride 9&nbsp;mg/ml (0.9%) Solution for Injection</p><p>Compound Sodium Lactate Intravenous Infusion</p><p>5% Glucose and Lactated Ringer&rsquo;s Intravenous Infusion</p><p>5% Glucose and 0.45% Sodium Chloride Intravenous Infusion</p><p>5% Glucose Intravenous Infusion</p><p>5% Glucose in 20 mEq Potassium Chloride Intravenous Infusion</p><p>0.45% Sodium Chloride Intravenous Infusion</p><p>5% Glucose and 0.9% Sodium Chloride Intravenous Infusion</p><p>&nbsp;</p><p>The compatibility of voriconazole with diluents other than described above or in section 6.2 is unknown.</p><p>&nbsp;</p><p>Instructions for reconstitution and use:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicinal product is for single use only and any unused solution should be discarded.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To prepare the VFEND vial for reconstitution, remove the plastic cap from the vial and wipe the top with an antiseptic swab. Hold the vial adapter over the vial and press down firmly, until the vial locks into place. The spike in the vial adapter will penetrate the vial seal.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The VFEND powder is reconstituted by using the specially marked syringe to remove 19 ml of solvent (Sodium Chloride (0.9%) from the blue port of the infusion bag.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The VFEND solvent for solution for infusion is then added to the vial by unscrewing the syringe from the bag, connecting it to the vial adapter and then emptying the contents from the syringe into the vial.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This will provide an extractable volume of 20 ml of clear concentrate containing 10&nbsp;mg/ml of voriconazole. The connected syringe and vial are then gently swirled to ensure that the VFEND powder has completely dissolved and no particulates are visible (do not shake).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For dilution, gently invert the vial, vial adapter and syringe assembly and withdraw <u>the required volume</u> of the reconstituted concentrate into the syringe (see table below). Only clear solutions without particulates should be used. <u>Do not administer to the patient as a bolus injection.</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Once the syringe is reconnected to the blue port of the infusion bag, the contents are then emptied into the infusion bag from the syringe to provide a final voriconazole solution containing 0.5-5 mg/ml.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The syringe may then be removed and the contents of the infusion bag mixed gently by inverting the bag several times. The bag should be carefully inspected to ensure that there are no particulates. The syringe, vial and vial adapter can then be discarded.</p><p>&nbsp;</p><p>If the required volume of VFEND concentrate as described in the table below requires the use of multiple vials in order to provide the appropriate dose for a given body weight, then multiple infusion kits should be used. The instructions should be followed for reconstitution, dilution and administration of each kit. Each kit is for single use only.</p><p>&nbsp;</p><p>If multiple vials are required, each individual vial used must be administered using a separate sterile sodium chloride bag.</p><p>&nbsp;</p><p>For administration, the twist-off port at the bottom of the infusion bag should be opened and the infusion line connected and primed. The contents of the infusion bag are now ready for infusion to the patient.</p><p>&nbsp;</p><p>The infusion bag should be checked to ensure that the entire contents of the bag have been infused, especially if the same intravenous line is to be used for sequential infusion of other drugs. Other additives should not be introduced into the infusion bag.</p><p>&nbsp;</p><p><strong><u>Required Volumes of 10 mg/ml VFEND Concentrate </u></strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>Body Weight (kg) </strong></p></td><td colspan="5"><p><strong>Volume of VFEND Concentrate (10 mg/ml) required for:</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>3 mg/kg dose (number of vials) </strong></p></td><td style="vertical-align:top"><p><strong>4 mg/kg dose (number of vials) </strong></p></td><td style="vertical-align:top"><p><strong>6 mg/kg dose (number of vials) </strong></p></td><td style="vertical-align:top"><p><strong>8 mg/kg dose (number of vials) </strong></p></td><td style="vertical-align:top"><p><strong>9 mg/kg dose (number of vials)</strong></p></td></tr><tr><td><p>10</p></td><td><p>-</p></td><td><p>4.0 ml (1)</p></td><td><p>-</p></td><td style="vertical-align:bottom"><p>8.0 ml (1)</p></td><td style="vertical-align:bottom"><p>9.0 ml (1)</p></td></tr><tr><td><p>15</p></td><td><p>-</p></td><td><p>6.0 ml (1)</p></td><td><p>-</p></td><td style="vertical-align:bottom"><p>12.0 ml (1)</p></td><td style="vertical-align:bottom"><p>13.5 ml (1)</p></td></tr><tr><td><p>20</p></td><td><p>-</p></td><td><p>8.0 ml (1)</p></td><td><p>-</p></td><td style="vertical-align:bottom"><p>16.0 ml (1)</p></td><td style="vertical-align:bottom"><p>18.0 ml (1)</p></td></tr><tr><td><p>25</p></td><td><p>-</p></td><td><p>10.0 ml (1)</p></td><td><p>-</p></td><td style="vertical-align:bottom"><p>20.0 ml (1)</p></td><td style="vertical-align:bottom"><p>22.5 ml (2)</p></td></tr><tr><td><p>30</p></td><td><p>9.0 ml (1)</p></td><td><p>12.0 ml (1)</p></td><td><p>18.0 ml (1)</p></td><td style="vertical-align:bottom"><p>24.0 ml (2)</p></td><td style="vertical-align:bottom"><p>27.0 ml (2)</p></td></tr><tr><td><p>35</p></td><td><p>10.5 ml (1)</p></td><td><p>14.0 ml (1)</p></td><td><p>21.0 ml (2)</p></td><td style="vertical-align:bottom"><p>28.0 ml (2)</p></td><td style="vertical-align:bottom"><p>31.5 ml (2)</p></td></tr><tr><td><p>40</p></td><td><p>12.0 ml (1)</p></td><td><p>16.0 ml (1)</p></td><td><p>24.0 ml (2)</p></td><td style="vertical-align:bottom"><p>32.0 ml (2)</p></td><td style="vertical-align:bottom"><p>36.0 ml (2)</p></td></tr><tr><td><p>45</p></td><td><p>13.5 ml (1)</p></td><td><p>18.0 ml (1)</p></td><td><p>27.0 ml (2)</p></td><td style="vertical-align:bottom"><p>36.0 ml (2)</p></td><td style="vertical-align:bottom"><p>40.5 ml (3)</p></td></tr><tr><td><p>50</p></td><td><p>15.0 ml (1)</p></td><td><p>20.0 ml (1)</p></td><td><p>30.0 ml (2)</p></td><td style="vertical-align:bottom"><p>40.0 ml (2)</p></td><td style="vertical-align:bottom"><p>45.0 ml (3)</p></td></tr><tr><td><p>55</p></td><td><p>16.5 ml (1)</p></td><td><p>22.0 ml (2)</p></td><td><p>33.0 ml (2)</p></td><td style="vertical-align:bottom"><p>44.0 ml (3)</p></td><td style="vertical-align:bottom"><p>49.5 ml (3)</p></td></tr><tr><td><p>60</p></td><td><p>18.0 ml (1)</p></td><td><p>24.0 ml (2)</p></td><td><p>36.0 ml (2)</p></td><td style="vertical-align:bottom"><p>48.0 ml (3)</p></td><td style="vertical-align:bottom"><p>54.0 ml (3)</p></td></tr><tr><td><p>65</p></td><td><p>19.5 ml (1)</p></td><td><p>26.0 ml (2)</p></td><td><p>39.0 ml (2)</p></td><td style="vertical-align:bottom"><p>52.0 ml (3)</p></td><td style="vertical-align:bottom"><p>58.5 ml (3)</p></td></tr><tr><td><p>70</p></td><td><p>21.0 ml (2)</p></td><td><p>28.0 ml (2)</p></td><td><p>42.0 ml (3)</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>75</p></td><td><p>22.5 ml (2)</p></td><td><p>30.0 ml (2)</p></td><td><p>45.0 ml (3)</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>80</p></td><td><p>24.0 ml (2)</p></td><td><p>32.0 ml (2)</p></td><td><p>48.0 ml (3)</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>85</p></td><td><p>25.5 ml (2)</p></td><td><p>34.0 ml (2)</p></td><td><p>51.0 ml (3)</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>90</p></td><td><p>27.0 ml (2)</p></td><td><p>36.0 ml (2)</p></td><td><p>54.0 ml (3)</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>95</p></td><td><p>28.5 ml (2)</p></td><td><p>38.0 ml (2)</p></td><td><p>57.0 ml (3)</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>100</p></td><td><p>30.0 ml (2)</p></td><td><p>40.0 ml (2)</p></td><td><p>60.0 ml (3)</p></td><td><p>-</p></td><td><p>-</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorisation Holder 
Pfizer Europe MA EEIG
Belgium

Manufacturer: 
Pharmacia & Upjohn Company LLC, 7000 Portage Road Kalamazoo, MI 49001, United States

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>